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     ABSTRACT 
  Gastrointestinal tract disease is the leading natural cause of death in horses and 
horses with ischemic intestinal disease have the greatest mortality. We hypothesized there 
is basal synthesis of endothelin-1 (ET-1) in the intestinal tract of healthy horses that is 
likely involved in regulating vasomotor tone, secretion and motility and that ET-1 
synthesis increases with gastrointestinal tract disease, which may be involved in the 
pathophysiology of these disorders. 
Plasma ET-like immunoreactivity was increased in horses with naturally-acquired 
gastrointestinal disease, compared with normal horses; values were greatest in horses 
with large intestinal strangulation obstruction, enterocolitis and peritonitis. There was an 
association between ET-1 levels and survival, PCV and duration of signs of pain. 
Immunohistochemical staining for ET-1 was present in surface epithelium, villi, 
muscularis and serosa of numerous intestinal segments in healthy horses. Staining was 
also present in submucosal vessels with veins staining more intense than arteries. 
Staining appeared more diffuse and intense in samples from horses with intestinal 
strangulation obstruction. Polymerase chain reaction analysis revealed the presence of 
ET-1 gene expression in numerous intestinal segments of normal horses. These findings 
suggest ET-1 is involved in physiologic functions such as regulation of secretion, 
vasomotor tone and motility, and that increased ET-1 with strangulation obstruction may 
be involved in the pathophysiology of these disorders. 
ET-1 caused sustained, concentration-dependent increases in cecal longitudinal 
smooth muscle tone in vitro, but the magnitude of contraction was less than that induced 
by carbachol. Pre-incubation of tissues with ETA (BQ-123) and ETB (IRL-1038) receptor 
 xiv 
 
antagonists alone did not inhibit ET-1 induced contraction. However, contractile 
responses were inhibited when tissues were incubated with both antagonists (10-5 M) 
together, suggesting both ETA and ETB receptors mediate the contraction. Electric field 
stimulation did not change the contractile response. 
These studies indicate a physiologic role of ET-1 in the equine gastrointestinal 
tract and that increased synthesis and release occurs with gastrointestinal tract disease, 
especially ischemic conditions, and may contribute to the pathophysiology of these 





























 Endothelin (ET), a potent vasoconstrictor, was first discovered in cultured porcine 
aortic endothelial cells. Since its discovery, numerous studies of the role of ET in various 
diseases have been conducted. Endothelin is synthesized in a variety of tissues and cell 
types, including endothelial cells, macrophages, mesangial cells, mast cells and 
astrocytes, where they modulate vasomotor tone, cell proliferation and hormone 
synthesis. Endothelin regulates blood flow in association with endothelium-derived nitric 
oxide (NO). Endothelin is also proposed to be an excitatory component of the non-
adrenergic, non-cholinergic innervation (NANC) of the enteric nervous system 
controlling gastrointestinal smooth muscle motility in conjunction with NO, an inhibitory 
component of the NANC system. 
 Endothelins are a family of vasoactive peptides that have potent vasoconstrictor 
actions. Of the three isoforms (ET-1, ET-2 and ET-3), ET-1 is implicated in the majority 
of physiological and pathological functions. Endothelin exerts its biologic activity by 
binding to its specific G-protein linked receptors, ETA and ETB. The ETA receptors are 
located on the vascular smooth muscle cells and binding of ET to ETA receptors mediates 
vasoconstriction. The ETB receptors are located on endothelial cells and in non-vascular 
smooth muscle cells where activation by ET-1 mediates dilation and constriction, 
respectively. The role of ET-1 has been implicated in several pathologic states including 
endotoxemia, sepsis, myocardial infarction, strangulation obstruction, ulcerative disease, 
ischemia-reperfusion and asthma. However, there have been no reports to date 
demonstrating a role of ET-1 in gastrointestinal tract disease of horses.  
 Intestinal strangulation is a common cause of colic that accounts for approximately 
10% of all the cases in horses with colic, and is universally fatal without surgical 
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intervention and intense medical therapy. Following surgical correction of experimental 
large colon volvulus in horses, the intestinal blood flow remains significantly decreased 
below baseline values for at least 4 hrs. This sustained reduction in blood flow is likely 
associated with disruption in the balance between endothelium-derived vasorelaxants 
(NO, PGI2) and vasoconstrictors (ET, PGF2α), resulting in ischemia, progressive mucosal 
damage and alterations in gastrointestinal motility. Although there are a plethora of 
mediators involved in the pathogenesis of ischemia-reperfusion injury, we propose that 
ET-1 is involved in the vasomotor abnormalities and subsequent ischemia. Increased 
plasma ET-1 concentrations have been found in various pathological conditions in other 
species such as low-flow states, sepsis and shock. We hypothesize that ET-1 is directly or 
indirectly involved in the cascade of events involving ischemia, ischemia-reperfusion 
injury (I-R) and motility disturbances in the gastrointestinal tract of horses.  
 The aim of the first study was to validate a commercially available 
radioimmunoassay (RIA) for measuring plasma ET-1 like immunoreactivity in horses, 
and to quantify and compare the circulating plasma ET-1 concentrations between healthy 
horses and in horses with naturally acquired gastrointestinal tract disorders. Additionally, 
we investigated the relationship between circulating plasma ET-1 concentrations and 
clinical, and clinicopathologic variables and the survival of the affected horses. We 
hypothesized that concentrations of plasma ET-like immunoreactivity would be greater in 
horses with naturally acquired gastrointestinal disorders, compared with healthy horses, 
and the survival of the horses would be inversely correlated with the increased plasma 
ET-like immunoreactivity.  
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 The aim of the second study was to validate ET-1 immunohistochemical staining in 
the gastrointestinal tract of horses, and to evaluate the presence and regional distribution 
of ET-1 like immunoreactivity in various segments of the gastrointestinal tract of healthy 
horses. Further, we evaluated alterations in the intensity of ET-1 staining in intestinal 
segments collected from horses with naturally acquired intestinal strangulation. We 
hypothesized that there would be an increase in intensity of ET-1 like immunoreactivity 
in the affected intestinal segment of horses with naturally acquired intestinal 
strangulation obstruction and this would correlate with the degree of intestinal damage. 
 The aim of the third experiment was to develop and validate a procedure for 
identifying the presence of ET-1 gene expression by polymerase chain reaction in 
intestinal sections collected from clinically healthy horses. We hypothesized that the ET-
1 would be found in variable quantities from various segments of the intestinal tract 
extending from the duodenum to the right dorsal colon of healthy horses. We also 
hypothesized that ET-1 gene expression would be greater in the mucosa of the jejunum 
and pelvic flexure of horses with naturally acquired small intestinal and large colon 
strangulation obstruction, respectively. 
  The aim of the fourth study was to identify and characterize the ET-1 induced in 
vitro responses of cecal longitudinal smooth muscle from clinically healthy horses devoid 
of any apparent gastrointestinal tract disorders.  The roles of ET receptors, ETA and ETB 
in ET-1 induced changes in the gastrointestinal tract smooth muscle contractility were 
evaluated using specific ETA and ETB receptor antagonists, BQ-123 and IRL-1038, 
respectively. Additionally, we clarified the role of ET-1 in nerve-mediated contractions 
induced by electric field stimulation. We hypothesized that ET-1 would be a potent 
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contractile agent in gastrointestinal tract smooth muscle. Additionally, we hypothesized 
that spontaneously contracting and EFS-stimulated ET-1 induced contractile and relaxing 
responses would be mediated by ETA and ETB receptors, respectively.   
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CHAPTER 2 























2.1 Anatomy of Equine Cecum and Colonic Viscera  
Knowledge of the anatomy of equine large intestine, including its gross anatomy, 
physiological function and basis of intestinal motility are necessary to understand the 
pathophysiologic mechanisms involved in various disease processes.  
2.1.1 Cecum 
The cecum is a large, comma shaped structure lying along the right dorsal to right 
ventral abdomen with its apex near the xyphoid process of the sternum. It is divided into 
three regions, namely the apex, body and base with blind ends at both extremities. The 
cecum has four teniae that form four rows of sacculations. The cecocolic orifice is 
located at the ventral part of the caudal cecal base. The vascular supply to the cecum is 
provided by the cecal arteries (lateral and medial), which arise from the ileocolic artery 
(Pfeiffer and MacPherson, 1990). 
The cecum is an important site of water and electrolyte absorption as well as 
microbial digestion of soluble and insoluble carbohydrates. The function of the cecum is 
to mix the ingesta constantly and retain it for a sufficient time to complete microbial 
digestion. There are four motility patterns recognized in the cecum (Ross et al., 1986). 
The first three are the haustral contraction patterns occurring every 20-30 sec that mix the 
contents of the cecum from the cranial base to the cranial apex. The fourth contraction is 
a progressive contraction pattern, which occurs once at approximately 4-minute intervals 
and originates every 4 minutes and originating from the pacemaker site in the cecal body 
or apex (Ross et al., 1986). Functional studies of the cecum have shown selective 
emptying of gas versus ingesta following contractions, and the prevention of reflux into 
the cecum from the colon due to an anatomic barrier, the cecocolic junction (Argenzio et 
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al., 1974).  Histologically, the cecum consists of a thin layer of muscularis externa, with 
flattened bands of smooth muscle and a high percentage of elastic fibers. The mucosa 
contains short, straight cecal glands with many goblet cells and cuboidal epithelial cells. 
The surface epithelium consists of tall columnar cells.   
2.1.2 Large Colon 
                               T he large colon or ascending colon is shaped as a double horseshoe looping 
from the right to left ventrally and then to the left and back to the right dorsally (Pfeiffer 
and MacPherson, 1990). It holds an average of 80 L and is approximately 4 m long. The 
diameter of the large colon varies considerably depending on the region, with the right 
dorsal colon being the largest. Branches of the ileocolic artery, colic branch artery and 
right colic arteries supply right and left ventral colon and right and left dorsal colon, 
respectively (Pfeiffer and McPherson, 1990). The pelvic flexure is a horse-shoe shaped 
segment of the large colon between the left ventral colon orally and to the left dorsal 
colon aborally. The pelvic flexure is situated in the left one-half of the abdomen and is in 
contact with the abdominal wall close to the pelvic inlet (Pfeiffer and MacPherson, 
1990). The pelvic flexure cannot be unfolded as its mesentery is attached to the 
mesocolon, which holds the ventral and dorsal colon parallel. The pelvic flexure is 
devoid of sacculations and is smaller in diameter (5.25 cm) compared with the left dorsal 
and ventral colons (9.25 cm) (Burns and Cummings, 1991). The abrupt narrowing of the 
pelvic flexure predisposes to impaction.   The right colic artery and colic branch artery 
anastomose at the pelvic flexure. Blood vessels enter the submucosa through the tunical 
muscularis and form the submucosal arteriolar plexus. Arterioles ascend from the 
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submucosal plexus to mucosa and form an extensive capillary network around the 
colonic glands.  
                                  The colon has a thin mucosal layer, with colonic glands separated by extensive 
lamina propria. The cells lining the colonic glands are goblets cells and granular cells 
(Pfeiffer and McPherson, 1990). The outer muscularis externa is thick and has bands of 
smooth muscle and elastic fibers (Pfeiffer and McPherson, 1990). A thin-layered 
muscularis mucosa is present, and villi are absent.  Few lymphoid follicles are also seen 
in the colon. 
 The main function of large intestine or ascending large colon is microbial 
fermentation of carbohydrates. Up to 75% of the energy requirement is met by the 
production of volatile fatty acids through the microbial digestion process. Further, a large 
quantity of fluid is secreted and resorbed (upto 95%) in the large colon (Argenzio et al., 
1974). 
2.2 Physiology of Gut Motility 
The control of gut motility is complex but well coordinated. Gastrointestinal 
motility is controlled and regulated by the enteric nervous system and modulated by a 
delicate interaction between myogenic, neural and humoral mediators. Gastrointestinal 
motility is affected by the ability of gastrointestinal smooth muscle to generate cyclic 
changes in the resting membrane potential. A basic pattern of electromyographic activity 
in the intestine characterized by a low frequency, low amplitude wave or basic electric 
rhythm (BER), with superimposing action potentials (spikes of high frequency and 
amplitude) has been established (Davies and Gerring, 1985).  
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The membrane potential of smooth muscle depends on the selective ion 
permeability of ions and NaK-ATPases within the membrane. The resting membrane 
potential (-60mV) triggers smooth muscle contraction through the influx of calcium ions 
(Casteels, Droogmans, Reaymaekers, 1989). Calcium ion channels are sensitive to 
change in the membrane potential. If the membrane potential exceeds threshold, these 
channels are active and result in a rapid increase in calcium concentration in the 
sarcolemma and initiate smooth muscle contraction. In the gastrointestinal tract, the 
resting membrane potential varies between –35 and –75mV, causing the BER.  The ion 
movements across the smooth muscle membranes generate the BER. Although the BER 
originates in the smooth muscle, it can be mediated by neural and humoral factors 
(Davies, 1989). 
Two recognized patterns of contractility are segmentation and peristalsis. 
Segmentation creates the slow aboral transit of ingesta and mixing ingesta with 
gastrointestinal secretions, whereas peristalsis promotes transit in an aboral direction 
(Davies, 1989). Peristalsis is accomplished by a combination of circular and longitudinal 
muscle contractions. During peristaltic movements, the longitudinal muscle acts first for 
long stretches and subsequently circular smooth muscle contract/relax initiating 
propulsive movements of the intestine. Other factors such as digesta viscosity, pressure 
gradients and gravitational forces are important in influencing gastrointestinal motility in 
horses (Weems, 1982). During the preparatory phase of peristaltic movement, circular 
smooth muscle relaxes and longitudinal muscle contracts and when filling pressure 
increases both circular and longitudinal smooth muscle contracts. Thus, shortening and 
constricting movements of the equine cecum occur by the synchronized contractions of 
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circular and longitudinal smooth muscle, occurring approximately every 4 minutes 
(Sellers and Lowe, 1986).  
The small intestinal contractions have an organized cyclical pattern, termed the 
migrating myoelectric complex (MMC). The motility pattern of the large intestine is 
more varied because the BER is present intermittently and at a variable frequency. Based 
on the duration of spike activity, two major patterns of electrical activity have been 
observed in the equine large colon. Short spike bursts (lasting < 5 sec) and long spike 
bursts (10-20 sec) are involved in mixing contractions, and in cecocolic retropulsion and 
colic propulsion, respectively (Ross, Rutkowski, Cullen, 1989). Extrinsic innervations of 
the large colon include parasympathetic fibers from vagal nerves and sympathetic fibers 
from the cranial mesenteric ganglia. Generally, parasympathetic stimulation tends to 
increase contractile activity of the gastrointestinal tract and sympathetic stimulation 
causes the opposite effect. In addition to its extrinsic innervation, the enteric nervous 
system plays an important role in the maintenance of gut motility. The enteric nervous 
system has two main plexi, namely the myenteric (Auerbach’s) plexus and the 
submucosal (Meissner’s plexus). The myenteric plexus is located between the circular 
and longitudinal smooth muscle layers and the submucosal plexus is positioned within 
the submucosa. The myenteric and the submucosal plexuses contain excitatory 
cholinergic neurons, excitatory and inhibitory adrenergic neurons, and excitatory and 
inhibitory non-adrenergic, and non-cholinergic (NANC) neurons (Boeckxstaens et al., 
1993). 
Gastrointestinal hormones or gut peptides such as gastrin, cholesytokinin, 
secretin, glucagon, motilin and pancreatic polypeptide tend to influence intestinal 
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motility, secretion, and blood supply. Prostaglandins (E and F) alter smooth muscle tone, 
and are found to be associated with visceral pain during mild colic (Roger and 
Ruckebusch, 1987). Compared with other intestinal segments, a greater number of 
ganglia and neurons per cm were found in the wall of the pelvic flexure suggesting the 
presence of a ‘pacemaker’ in the region (Schusser and White, 1997). Neurotransmitters 
such as substance-P, methionine-enkephalin, calcitonin gene-related peptide and 
vasoactive intestinal peptide (VIP) were found in the wall of the pelvic flexure (Burns 
and Cummings, 1993). Studies have shown that injury to the myenteric plexus during 
strangulation obstruction may permanently reduce the neuronal density, leading to 
compromise of function and possibly development of an impaction (Schusser, 
Scheidemann, Huskamp, 2000). This finding is in agreement with a higher incidence of 
colic in horses with history of large colon impaction (Dabareiner and White, 1995). 
Sellers & Lowe (1986) proposed that malfunction of the pelvic flexure pacemaker is one 
of the reasons for large colon displacement and torsion. 
2.2.1 Motility Disturbances 
 In horses, various gastrointestinal tract disorders such as ischemia,ischemia-
reperfusion (I-R) injury, impaction, endotoxemia, and parasitism result in disturbances of 
gastrointestinal motility. Various endogenous mediators, electrolyte imbalances and 
neural factors are involved in the pathogenesis of intestinal dysmotility associated with 
abdominal disorders. Postoperative ileus results from disruption in the balance between 
the excitatory and inhibitory neurotransmitters secondary to inflammation, endotoxemia 
and intestinal distention (Bilkslager et al., 1994).  Disruption in cecal motility and 
emptying may be a key factor in the etiopathogensis of cecal impaction (Collatos and 
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Romano, 1993). However, the mechanism has not been fully elucidated mainly due to an 
insufficient understanding of neurohumoral control of gastrointestinal motility.  
 Experimentally-induced pelvic flexure impactions in ponies caused mild persistent 
colic characterized by increased large colon contractile activity (Lowe, Sellers, Brondum, 
1980).  In experimentally-induced extraluminal obstruction in ponies, the motility of 
intestine proximal to the obstruction was increased. In horses, endotoxemia has been 
shown to cause cecal and proximal colonic ileus and cecal hypoperfusion through a 
mechanism involving alpha-2 adrenergic receptors (Eades and Moore, 1993).  
 Ischemia-reperfusion injury leads to profound functional and structural alterations 
in the activity of the gastrointestinal tract. In rats, I-R injury is characterized by functional 
dysmotility of the duodenum and jejunum with prolonged duration of contraction and a 
decreased number of contractions, respectively (Takahashi et al., 2001). In addition, the 
interdigestive MMC cycling time was found to increase during the ischemic period in 
experimentally induced I-R model in piglets, with no change during reperfusion (Hebra et 
al., 1993). The impaired motility during I-R is attributed to the release of superoxide and 
other vasoactive mediators such as ET and NO. 
2.3 Regulation of Intestinal Blood flow  
2.3.1 Role of Endothelium  
 Endothelium is a metabolically active layer, consisting of a single layer of flattened 
and polygonal cells lining the circulatory system (Bennet, Luft, Hampton, 1959). These 
cells are coated with a carbohydrate-rich cell coat, glycocalyx, consisting of 
glycosaminoglycans and polysaccharide chains of the plasma membrane glycoproteins 
and glycolipids (Borsum, 1991). Vascular endothelium is increasingly recognized as the 
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central mediator of a number of important processes in vascular biology and disease. 
Until recent years, it was considered simply as a barrier between blood and extravascular 
tissue. However, endothelial cells play a pivotal role in the balance between coagulation 
and fibrinolysis, immune responses, regulation of blood pressure and perfusion, and 
mediate local inflammatory responses (Pearson, 1991).  
 Recent studies have demonstrated that endothelium plays a critical role in 
regulation of vascular tone by releasing various vasoactive mediators such as endothelial-
derived vasorelaxant (NO, prostacyclin) and vasoconstrictor (ET, prostaglandins) agents, 
which are major determinants in maintaining blood flow. Endothelial damage can disrupt 
the balance between vasorelaxant and vasoconstrictor substances, which lead to increased 
vasosmotor tone, resulting in increased intestinal vascular resistance and subsequent 
reduction of blood flow. The most likely endothelium-derived vasoactive mediators 
involved are NO and PGI2 (vasorelaxants) and ET-1 (vasoconstrictor). 
2.3.2 Endothelin and Nitric Oxide 
 Various endothelial-derived contracting and relaxing factors are released following 
humoral, mechanical and neural stimulation of the endothelium, and the balance between 
these factors is responsible for the control of vascular tone and blood flow (Brenner, 
Troy, Ballerman, 1989). Endothelial cells synthesize NO (vasodilator, inhibits platelet 
aggregation and neutrophil adhesion) and ET-1 (vasoconstrictor and platelet aggregator). 
The opposing effects of NO and ET on vascular smooth muscle suggests a regulatory role 
of endothelium regarding blood flow and vasomotor tone. Inactivation of NO synthase 
and prostaglandin synthesis by N-ω-nitro-L-arginine methyl ester (L-NAME) and 
indomethacin, respectively, augmented ET-1 induced contractility in rabbit coronary 
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smooth muscle, which impaired coronary blood flow (Berti et al., 1993). The impaired 
blood flow during intestinal obstructive disorders in various species may be due to an 
imbalance of these mediators (increased ET-1 and decreased NO).  
 Because of its high metabolic activity and subsequent requirement for blood flow, 
the gastrointestinal tract mucosa is a primary target tissue of low-flow conditions such as 
hemorrhagic or endotoxin shock (Patel, Kaleya, Sammartano, 1992). One of the principal 
homeostatic mechanisms for the host’s response to reduced circulating blood volume 
(hypovolemic or endotoxin shock) is to shunt blood away from the gastrointestinal tract 
in an attempt to increase the effective blood volume and maintain perfusion of vital 
organs (Patel, Kaleya, Sammartano, 1992). The maintenance of blood flow and cardiac 
output is achieved mainly through intense sympathetic stimulation, and by other humoral 
and vasoactive mediators. The release of sympathetic mediators (epinephrine, nor-
epinephrine) during these conditions causes strong vasoconstriction of arterioles, and 
large capacity intestinal and mesenteric veins, thereby displacing the blood volume from 
other parts of the circulation (splanchnic) and increasing total peripheral resistance and 
venous return. The gastrointestinal tract tissues have high resting O2 uptake (20-25 
mL/kg/min) that is normally met by a high blood flow rate (300-500 mL/kg/min) 
(Guyton, 2000). If blood flow falls below critical values and the O2 uptake is 
compromised, intestinal damage ensues. Thus, gut circulation appears to be more 
susceptible to the vasoconstrictor properties of ET-1 than many other peripheral vascular 
beds.  
 The role of splanchnic ischemia or hypoxia in the pathogenesis of shock has 
stimulated much interest in the mechanism of intestinal ischemia. Haglund & Lundgren 
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(1987) suggested the presence and induction of unknown vasoactive substances that 
reduced the intestinal perfusion or caused systemic shock during low-flow conditions in 
the intestine and even after surgical correction of intestinal strangulation obstruction. This 
reduction in blood flow is probably due in part to splanchnic vasoconstriction, where 
humoral mediation is likely critical and is achieved through the release of endothelial-
derived mediators. The sensitivity of the intestinal vasculature to ET-1 may be of 
considerable importance considering the fact that ET-1 levels are increased in a variety of 
instances such as chronic hypoxia, ischemia and sepsis (Cernacek and Stewart, 1989; 
Weitzberg et al., 1991; Murch et al., 1992; Fevang et al., 1998). 
 Non-selective agents should be avoided during pharmacological intervention of 
splanchnic circulation. Various experimental data suggest that therapeutic approaches 
using selective ET blockers and/or NO donors are beneficial in the treatment of I-R injury 
(Oktar et al., 2002; Kalia et al., 2001). The prevention of splanchnic vasoconstriction 
using vasodilators has been used in human gastrointestinal surgery (Gentilini et al., 
1999). Selective agents, such as prostaglandin E and glucagons are used to increase 
mucosal blood flow. Studies have shown that captopril, an angiotensin antagonist, can 
also be used to disrupt angiotensin (vasoconstrictor) secretion during I-R (Guo et al., 
1998). Anticoagulants have been advocated for use in gastrointestinal surgery to prevent 
intravascular thrombosis and or/emboli. Heparin administration was found to improve 
colonic blood flow, vascular resistance and systemic arterial blood pressures in 
experimentally-induced colonic transmural and vascular obstruction for 1 hour in ponies 
(Provost et al., 1991). The mechanism of action of heparin lies in its ability to act as a co-
factor together with antithrombin III (AT-III), causing increased AT-III as an inhibitor of 
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activated clotting factors. However, few studies have shown the beneficial effects of 
using these agents to improve equine intestinal blood flow after ischemia. 
2.4 Endothelin 
 The role of endothelium in the regulation of vasomotor tone was elucidated by the 
discovery of vasorelaxants synthesized from endothelial cells (prostacyclin, NO) 
(Moncada et al., 1976; Furchgott and Zawadzki, 1980). Studies have shown that 
endothelium also releases a vasoconstricting peptide, termed endothelial-derived 
constricting factor (EDCF) (Hickey et al., 1985). This peptidergic substance was later 
purified from supernatant of porcine aortic endothelial cell culture medium, and was 
termed endothelin (Yanagisawa et al., 1988). Cloning and sequence analysis has since 
revealed three distinct endothelin-related genomic loci in human, pig and rat that encodes 
for three similar but distinct peptides, ET-1 (formerly called porcine or human 
endothelin), ET-2 and ET-3 (formerly called rat-ET) (Yanagisawa et al., 1988; Itoh et al., 
1988; Inoue et al., 1989). In addition, sarafotoxin (STX) has also been included in the ET 
family due to its remarkable similarities in homology and bioactive properties. The 
presence of ET in invertebrates and fish indicates its long evolutionary history (Kasuya et 
al., 1989). 
 Endothelins are a family of 21-amino acid peptides (MW 2492) and are the most 
potent vasoconstrictors known to date. Endothelins are multifunctional peptides that have 
vasoactive, ionotropic, and mitogenic properties (Rubanyi and Polokoff, 1994), and have 
the ability to modulate other hormone systems as well as intestinal, renal and pulmonary 
function. Expression of ET in non-vascular cells/tissues suggests its diverse role in 
physiological and pathological processes (Levin, 1995; Rubanyi and Polokoff, 1994). 
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These diverse and complex functions include neurotransmission, stimulation of intestinal 
contraction (motility), synthesis of atrial natriuretic factor (ANF), counter-balancing NO 
release, inhibition of renin release and control of sympathetic tone (Levin, 1995). 
2.4.1 Biology of ET 
 The human ET-1 gene sequence found in chromosome 6 is 6.8kb in size and 
encompasses 6 exons and 5 introns. Each portion of the exon encodes a portion of ET-1, 
and exon 2 encodes the majority of prepro-ET-1 (Lee et al., 1990). The promotor region 
has the typical CAAT and TATA sequences regulating transcription and has several 
responsive elements, which provide regulatory sites for various stimuli (Lee et al., 1990). 
The genes for ET-2 and ET-3 are located on chromosome 1 and 20, respectively. The 
equine ET-1 has not been completely sequenced, however, a group of scientists have 
cloned and published the partial sequence of chromosomal ET-1 gene (Gene Accession # 
AF130760).  
2.4.2 Endothelin Isoforms 
 Each of the isoforms of ET is a product of separate genes that encode the large 
precursor, prepro-ET. Endothelin-1, is the predominant type of ET, but ET-2 and ET-3 
also exist. Vasointestinal constrictor (VIC), also known as β-endothelin, has been 
demonstrated in murine intestine (Inoue et al., 1989) and differs from ET-1 by three 
amino acids (in positions 4, 6 and 7). 
 Endothelin-1 is the most abundant circulating ET isoform, and has been best 
characterized (Rubanyi and Polokoff, 1994). Of all the endothelin types, the principal ET 
of importance in vascular diseases is ET-1, and is the only isoform synthesized by the 
endothelium. Endothelin-1 is also found in smooth muscle, airway epithelium and other 
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cell types. The ET-1 and ET-3 isoforms have been found in nearly every organ examined 
including different segments of the gastrointestinal tract of rats (Matsumoto et al., 1989; 
Firth and Ratcliffe, 1992).  The ET-3 isoform also circulates in the plasma and is found in 
the central nervous system, kidney and lung, however, the cellular source is not clear 
(Hemsen and Lundberg, 1991). The presence of ET-3 in the brain suggests its role in 
important functions including astrocyte proliferation and development (Shinmi et al., 
1989). However, the expression of ET-2 is much more limited and found predominantly 
in the kidney and intestine, where its function remains unclear (Levin, 1995). 
2.4.3 Biosynthesis of ET 
 Endothelin levels are controlled at the level of transcription of its precursor, 
preproendothelin (preproET). Endothelin isoforms are processed from prepro-ET to form 
pro-ET, which is then post-translationally converted into the active peptide, ET. 
Endothelins are derived from unusual proteolytic cleavage of large pre-proET 
(approximately 203 amino acid) by specific dibasic endopeptidases. Each pre-proET has 
a distinct gene and amino acid sequence processed to the polypeptide prohormone, big 
ET, of various lengths (37-41 amino acids). The polypeptides (big ETs) are cleaved in the 
cytoplasm by the proteolytic action of membrane-bound metalloproteinases, endothelin-
converting enzymes (ECE), into ET and a C- terminal fragment-1 (CTF-1) (Figure 2.1). 
The big ET-1 has very low biologic activity. The enzymatic process of the synthesis of 
mature ET-1 occurs by unusual proteolytic cleavage of big ET-1 between Trp21 and Val22 
by ECE (in case of big ET-3 it is between Trp21 and Ile22) (Opgenorth, Wu-Wong, 
Shiosaki, 1992). The conversion of big ET-1 to ET-1 by ECE is essential for the 






















Figure 2.1 Biosynthesis of endothelin-1. Abbreviations: S-S – disulfide bond; CR- 




1b, ECE-1c, ECE-2 and ECE-3 have been cloned and classified (Turner and Murphy, 
1996; Schweizer et al., 1997), each with a different tissue distribution and pH 
requirement for activity. Each bioactive form of the ET isoforms is synthesized by 
specific conversion between Trp21-Val22 and Trp21-Ile22. The ECE isoforms are found in 
many cell types including endothelium, epithelium and alveolar macrophages (Takahashi 
et al., 1993; Ohnaka et al., 1990). However, ECEs have not yet been identified that are 
selective for ET-2 and ET-3. Greater than 80% of the ET-1 synthesized by the 
endothelium is secreted abluminally toward the tunica media away from the luminal 
surface of the airway or vessel (Wagner et al., 1992). Directional secretion allows ET-1 
to act in a paracrine or autocrine manner whereas secretion into the circulation allows 
ET-1 to act as a hormone. 
 The half-life of ET mRNA is 20-30 minutes, whereas the ET peptide has an 
extremely short half-life of 4-7 minutes. Endothelins are stable in plasma, predominantly 
cleared or metabolized in the lung during their first passage (90%), and excreted in small 
amounts via the kidney and liver (de Nucci et al., 1988). In rats and humans, the lung is 
responsible for ET-1 elimination; however, in pigs the renal and splanchnic circulation 
are involved in ET-1 clearance. Some studies suggest that ET is eliminated from blood 
quickly and is likely followed by the internalization of the peptide into the tissue 
parenchyma and/or vasculature of various tissues (Anggard et al., 1989; Shiba et al., 
1989). The pathway of ET synthesis is well defined, but its complex process of 
degradation, which also determines its biologic activity, is not completely understood.  
2.4.4 Endothelin Structure 
 Endothelin is a family of 21 amino acid peptides with free amino and carboxy- 
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terminal, which include four cysteine residues at positions 1, 3, 11 and 15, forming two 
intra-molecular disulfide linkages between Cys1 and Cys15, and Cys3 and Cys11 
(Yanagisawa et al., 1988). The presence of the disulfide bonds provides a compact NH2 
terminal core region consisting of outer and inner loops. The disulfide bonds present in 
ET are vital to its high affinity binding to one class of ET receptors, but are of less 
importance in recognition by the other class of ET receptors. Amino acid residues 4-7 
comprise the variable region, residues 12-14 are highly unpolar regions, and residues 16-
21 are hydrophobic. The hydrophobic C terminus in all three ET isoforms is strictly 
conserved. The terminal tryptophan region of ET has been shown to be essential for its 
full biologic activity. The ET-2 isoform exhibits the closest structural similarity to ET-1, 
differing by only two amino acid residues at positions 6 and 7, whereas ET-3 differs from 
ET-1 by six amino acids at positions 2, 4, 5, 6, 7 and 14 (Figure 2.2). These peptides 
exhibit different degrees of vasoactivity and it has been suggested that the overall charge 
of the inner Cys-Cys loop may be an important determinant of this property (Kloog and 
Sokolovsky, 1989). 
 2.4.5 Endothelin Receptors 
 The use of radiolabelled ET in autoradiographic and standard ligand binding studies 
has demonstrated that the ET isopeptide binding sites are distributed in a wide variety of 
both adult and fetal organs and tissues in different species (Davenport et al., 1989; 
Takayanagi et al., 1991). The binding sites have been shown in locations such as the 
central nervous system, lung, gastrointestinal tract (stomach, small intestine and colon) 
and within the cardiovascular system (Power et al., 1989; MacCumber, Ross, Snyder, 
1990). Two independent groups have reported the cloning, sequencing and functional 
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expression of endothelin receptors (Arai et al., 1990; Lin et al., 1991). Two types of ET 
receptors were cloned, termed endothelin A (ETA) and endothelin B (ETB) with size 
ranging between 45,000-50,000 daltons. The ETA and ETB receptor 
genes are located on human chromosomes 4 and 13, respectively (Arai et al., 1990; 
Sakurai et et al., 1990). There is a high degree of sequence identity at the amino acid 
level (90%) between the receptor subtypes, however, little homology is found between 
the two receptor types, ETA and ETB. The greatest diversity occurs in the extra-cellular 
domain and in the cytoplasmic COOH region. Both ET receptors (ETA and ETB) belong 
to a family of heptahelical G-protein-coupled receptors. The ET receptors have an 
extracellular NH2 terminal region, transmembrane helices separated by 3 extracellular and 
3 cytoplasmic loops with a terminal cytoplasmic COOH region. Endothelin is hydrophilic 
and thus unable to cross plasma membranes. The saturable binding sites are present in the 
cell wall, and it is presumed that ET acts by binding to these receptors.  
 All three ET isoforms bind to their distinct receptors in mammalian cells that have 
different affinities to endogenous ligands. The two main types of ET receptors found in 
smooth muscle and endothelium are ETA and ETB, respectively. These receptor types 
originally identified in the vasculature have also been found in many other organs such as 
the liver, brain, kidney and gastrointestinal tract, with the greatest concentrations in heart 
and lung; this suggests ET’s pleiotropic function. The ETA receptor is principally found 
in vascular and airway smooth muscle cells and has 10 times more binding affinity for 
ET-1 than for ET-3 (Rubanyi and Polokoff, 1994). The affinities for binding of the ET 
isoforms to ETA receptors are in the order: ET-1 > ET-2 > ET-3 (Rubanyi and Polokoff, 




























Figure 2.2 Endothelin isoforms. The dark colored circle represents variable amino acid                 




and ETB2. The ETB1 receptors are found in the endothelium and mediate the release of 
NO and prostacyclin causing vasodilatation (de Nucci et al., 1988; Sakurai et al., 1990), 
whereas ETB2 receptors on the smooth muscle mediate vasoconstriction. Thus, binding of 
ET-1 with ETA receptors leads to constriction and with ETB1 causes dilatation. The 
difference in tissue-specific expression between ET receptor types and subtypes 
contributes to the different actions of endothelin. Within a particular tissue, the 
distribution of ETA and ETB receptors varies. Consistent with functional activity of ET-1 
in intestinal smooth muscle, ET-1 binding sites have been documented in the stomach, 
ileum, jejunum, and colon of rats (Koseki et al., 1989; Takahashi et al., 1990) and guinea 
pig (Bolger et al., 1992). In the kidney, the ETA receptors are found predominantly in the 
vasa recta whereas ETB is found mostly in the collecting ducts (Simonson, 1993). In 
horses, a genetic polymorphism of the ETB receptor is linked to the Overo Lethal White 
Foal Syndrome in paint foals, characterized by spastic colon and intestinal 
aganglioneurosis (Yang et al., 1998). 
2.4.6 Endothelin Signal Transduction Mechanism 
                     Endothelins bind to receptors and elicit their effects, such as vasoconstriction and 
vasodilatation, via signal transduction pathways through G-protein activation (Figure 
2.3). The G-proteins have various subunits such as Gs, Gi and Gq. The Gs alpha subunit 
primarily activates adenylyl cyclase that catalyzes the formation of cAMP from ATP. 
The Gi alpha subunit inhibits adenylylate cyclase. The Gq alpha subunit activates 
phospholipase C (PLC) that cleaves phosphotidylinositol-4, 5-bisphosphate (PIP2) in the 
cell membrane to release diacylglycerol (DAG) and inositol-(1, 4, 5)-triphosphate (IP3). 
The principal protein affected by the activation of phospholipases is protein kinase-C 
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(PKC), which is maximally active in the presence of calcium ion and DAG. The PLC 
contains SH2 domains that allow it to interact with tyrosine phosphorylated receptor 
kinases. This allows PLC to be intimately associated with the signal transduction 
complexes of the membrane as well as membrane phospholipids that are its substrates.  
The phosphoinositide cascade is mediated by membrane bound enzyme PLC, 
which is activated by ET binding to its receptors (Simonson et al., 1989). The IP3 causes 
the release of Ca2+ stores in the endoplasmic reticulum and sarcoplasmic reticulum, 
increasing the levels of Ca2+ in the cytosol. The increased level of cytosolic Ca2+ then 
causes smooth muscle or vascular contraction. The DAG and Ca2+ activate PKC, 
catalyzing phosphorylation of serine-threonine residues of various target proteins 
mediating mitogenic action.  
Endothelin-induced contraction is mediated by the activation of nonselective 
cation channels permeable to calcium (Zhang et al., 2000). The binding of ET to its 
receptor leads to the activation of Gsα subunit of adenylyl cyclase, forming cAMP from 
ATP. The cAMP acts as an intracellular messenger and catalyzes various other cellular 
functions. The ET-induced vasoconstriction is a biphasic response, whereby a period of 
transient vasoconstriction is followed by a distinct and sustained vasoconstriction. The 
transient vasoconstriction observed with ET release is attributed to the release of Ca2+ 
from the intracellular calcium stores and the characteristic sustained vasoconstriction is 
mediated mainly through the persistent entry of extracellular calcium through calcium 
channels of the plasma membrane (Masaki, 2000). The vasodilator action of the ET-
activated receptor, ETB1, is attributed to the release of NO and prostacyclin or increased 
levels of cGMP through activation of Gi. The Gi activation has been shown to cause 
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inhibition of adenylate cyclase and activation of the Na+-H+ antiporter (Aramori and 
Nakanishi, 1992; Koh et al., 1990). Another function of the ET receptor is to mediate the 
growth activity of cells such as smooth muscle or endothelial cells (mitogenic). This 
activity is mediated through various mechanisms, i.e., classical PKC-dependent and -
independent pathways.  
2.4.7 Endothelin Receptor Antagonists 
                      A number of ET receptor antagonists have been developed and tested in animal 
models. The first ET antagonist developed for human testing was a natural by-product of 
Streptomyces misakiensis. However, this ET antagonist has low binding and functional 
properties. A series of peptide antagonists for endothelins selective toward ETA (BQ 
123), ETB (BQ 788, IRL-1038 ) and both ET-A/ET-B receptors (PD 142893, TAK-044, 
RO 46-2005) have been designed. A competitive ET antagonist, BE-18257, a cyclic 
pentapeptide was shown to have very low potency in binding and functional assays 
(Benigni and Remuzzi, 1999). These compounds are hydrolyzed by circulating 
peptidases, and do not penetrate the blood brain barrier when given orally (Benigni and 
Remuzzi, 1999). Recently, synthetic non-peptide antagonists have been developed (PD 
155080-Bosentan, BMS 182874, SB 209676) and they prodced mixed results (Benigni 
and Remuzzi, 1999).    
2.4.8 Factors Involved in ET-1 Expression and Secretion      
       Endothelin-1 levels are controlled at the level of transcription of its precursor, 
preproendothelin-1. The upstream regulatory element of the ET gene contains an acute 




































Figure 2.3 Mode of action involved in ET-1 induced constriction, relaxation and 
mitogenesis. VOC-voltage operated channel, PKC-protein kinase C; DAG- 
diacylglycerol; IP3- inositol triphosphate; NO- nitric oxide; PLC- phospholipase 
C PIP2- phosphatidylinositol biphosphate; MLC-myosin light chain; MLC-P- 
phosphorylated myosin light chain; PGE2-prostaglandin E2; PGI2-prostoglandin 




1989). The ET-1 synthesis is controlled by a number of physical and humoral factors 
(Kurihara et al., 1989; Emori et al., 1989; Kourembanas et al., 1991; Kanse et al., 1991; 
Malek and Izumo, 1992). The physical factors include shear stress and hypoxia. The 
humoral factors involved in ET-1 synthesis are hormones (vasopressin, angiotensin, 
epinephrine, insulin), bradykinin, cytokines (tumor necrosis factor-(TNF)-α, interleukin- 
(IL)-1), growth factors such as transforming growth factor (TGF)-β, platelet activating 
factor (PAF) and endotoxin. The suppressors include NO, atrial natriuretic factor (ANF) 
and cGMP. 
 2.4.8.1 Physical Factors 
        Low shear stress causes increased ET-1 mRNA expression and ET release in 
cultured aortic endothelial cells (Yoshizumi et al., 1990). However, bovine aortic 
endothelial cells exhibited a dose-dependent decrease in ET-1 mRNA expression with 
increased shear stress (Malek and Izumo, 1992). Also, Kourembanas et al. (1991) 
demonstrated increased ET-1 mRNA expression in cultured human umbilical vein 
endothelial cells to low oxygen tension. 
 2.4.8.2 Humoral Factors  
 Cytokines such as TNF and IL-1 are identified as the primary mediators in the  
pathogenesis of sepsis and are important modulators of ET-1 secretion (Kahaleh and Fan, 
1997, Kruse-Elliot, Whorton and Olson, 1998). In vitro ET synthesis increases in cultured 
porcine aortic endothelial cells stimulated with TNF and IL-1 (Kanse et al., 1991; 
Yoshizumi et al., 1990). Also, IL-1 and IL-1β increase ET-1 mRNA levels and ET 
synthesis in a dose-dependent manner (Yoshizumi et al., 1990). It is speculated that an 
IL-1-endothelin axis exists between macrophages and smooth muscle cells, which 
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implicates its role in vasospasm.  But additional studies have shown that IL-1β, IL-6 and 
IL-8 have no effect on ET-1 synthesis and release from cultured endothelial cell, whereas 
interferon-γ and TNF have only a small effect (Kanse et al., 1991). 
 Cytokines released by activated platelets such as TGF-β induces ET-1 gene 
expression by binding to nuclear factor-1 (NF-1) (Kanse et al., 1991), but the role of TGF 
in modulation of ET-1 secretion during I-R is unknown. Various hormones like 
vasopressin and angiotensin-II induce an increase in endothelial ET-1 mRNA levels 
(Emori et al., 1989). The induction and secretion of ET-1 by TGF-β in endothelial cell 
cultures is in a manner similar to thrombin (Kurihara et al., 1989). Thus, during vascular 
injury and thrombin formation, ET-1 may play a role in local constriction via the release 
of TGF-β from activated platelets. Taken cumulatively, these results suggest that the 
production of ET-1 in endothelial cells is regulated by factors associated with platelet 
aggregation and macrophage infiltration.  
 Tumor necrosis factor, an important primary mediator of endotoxemia, increases 
the transcriptional rate of the ET-1 gene (Marsden and Brenner, 2000). Endotoxin 
stimulates monocytes/ macrophages to release TGF, IL-1 and IL-6 (Morris, 1991, Morris 
et al., 1992). These mediators initiate and perpetuate a cascade of inflammatory events 
that can lead to endotoxic shock and multiple organ failure. Stimulation of cultured 
vascular smooth muscle cells with TNF-α (10 ng/mL), IFN-γ (1,000 U/mL), IL-1β (500 
U/mL) and lipopolysaccharide (10 micrograms/mL) for 48 hrs markedly increase the ET-
1 mRNA expression and ET-1 secretion (Woods et al., 1998). This suggests that these 
mediators, TNF and IL-1, released during endotoxemia may stimulate and augment 
synthesis and release of ET from the vascular endothelium.    
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2.5 Colic 
 Gastrointestinal tract disease is the leading natural cause of death in adult horses, 
(Baker and Ellis, 1981) and most horses are afflicted by colic sometime during their 
lifetime. Acute gastrointestinal tract diseases of the equine abdomen associated with pain 
are termed ‘colic’. The mortality rate for colic was shown to be the highest of any cause 
of death in horses, including old age and injury (Tinker et al., 1997). The etiology and 
pathophysiology of colic is complex and varied. 
 Small intestinal strangulating obstruction secondary to twisting around its 
mesentery or incarceration and strangulating large colon volvulus are common causes of 
colic in horses, and are associated with high mortality (Barclay, Foerner, Phillips, 1980; 
Harrison, 1988; MacDonald et al., 1989). The poor prognosis for survival following 
surgical correction of intestinal strangulation obstruction in horses despite appreciable 
advances in medical care is associated with a sustained reduction in intestinal blood flow 
and mucosal perfusion with changes in microvascular permeability leading to edema, 
congestion, hemorrhage, and ultimately, necrosis of the mucosal layer (Snyder et al., 
1990; Wilson et al., 1994; Darien et al., 1995). 
 Most cases of naturally acquired intestinal strangulation obstruction in horses 
involve simultaneous arterial and venous occlusion, with venous occlusion being more 
predominant. Strangulating obstruction of the large colon and small intestine are the most 
common causes of vascular occlusion in horses with colic (Barclay, Foerner, Phillips, 
1980; Huskamp, 1982). Vascular occlusion of the intestine may be induced by parasitism, 
with subsequent thromboembolism, and or by strangulation obstruction. Intestinal 
ischemia (strangulating large colon volvulus and small intestinal strangulation 
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obstruction) is universally fatal without surgical intervention. Up to one-half of the deaths 
attributed to colic are associated with lesions in the large intestine (Pascoe et al., 1983).  
 Ischemic injury to the mucosal epithelium occurs predominantly during 
strangulation obstruction; however, intestinal injury can progress after surgical correction 
owing to either continued ischemia associated with microvascular thrombosis or 
splanchnic vasoconstriction during the postoperative period. Intestinal blood flow has 
been shown to remain significantly depressed below the baseline values for at least four 
hours after correction of experimentally induced complete arteriovenous occlusion of the 
large colon in ponies (Wilkins et al., 1994). Thus, even after surgical correction and/or 
resection of affected intestine the remaining intestine is predisposed to continued 
ischemic damage resulting in increased mortality (Fischer and Meagher, 1986). 
Alternatively, damage induced by ischemia likely continues after blood flow is restored, 
which is initiated by cytotoxic reactive oxygen metabolites and perpetuated by 
neutrophils and other mediators (Moore, Muir, Granger, 1995). This process is known as 
ischemia-reperfusion injury. Endotoxemia is estimated to occur in nearly 25% of horses 
with colic; most of these cases involve intestinal ischemia or inflammation (King and 
Gerring, 1988). The high mortality subsequent to intestinal ischemia is associated with 
disruption of the intestinal mucosal barrier, which allows translocation of luminal 
endotoxin and bacteria into the systemic circulation, resulting in endotoxemia and 
circulatory shock. Thus, eventually horses succumb to the effects of endotoxic and 
hypovolemic shock.  
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2.5.1 Classification of Colic  
Colic can be classified into various types based on the etiology and the intestinal 
segment involved.  Colic has been anatomically and functionally classified as simple 
obstruction, strangulating obstruction, non-strangulating infarction, enteritis, peritonitis, 
ulceration and ileus (Tinker et al., 1997). The non-specific colic cases without definitive 
diagnosis are referred commonly as medical, spasmodic, flatulent, or mild colic; and may 
be attributed to numerous factors including diet or parasites (Parry, 1983).  
 2.5.1.1 Simple Obstruction - Impaction 
 Simple obstruction of the intestine involves luminal obstruction without vasucular 
compromise, the most common of which is the impaction of the intestinal tract. This type 
of simple obstruction is more common in horses, and accounts for nearly 30% of all colic 
cases admitted to referral centers (Dabareiner and White, 1995). Impaction results from 
accumulation of ingesta in the intestinal tract, which may be due to abnormalities in 
myogenic, humoral and neurogenic control of gut motility (Stanghellini, 1988), thereby 
disrupting aboral propulsion of ingesta. Obstruction and dehydration of ingesta in the 
gastrointestinal tract also lead to impaction.   
 Impaction often develops at sites of narrowed luminal diameter such as the pelvic 
flexure or just proximal to the transverse colon in the right dorsal colon. The common 
sites for impaction in the horse include the ileum, cecum, pelvic flexure, right dorsal 
colon and small colon (White and Dabareiner, 1997). Partial obstruction is more common 
in the cecum, large colon and small colon, where gas and fluid often pass around the 
ingesta. Cecal impaction is the most common cause of cecal disease and obstruction, 
accounting for up to 5% of colic cases admitted to US veterinary teaching hospitals. 
 34
Cecal impaction is more common in the cranioventral part of the cecal base (White, 
1980). Local distention due to the impacted mass can causes alterations in circulation to 
the bowel wall, thereby increasing capillary permeability and loss of fluid and protein 
into the peritoneal cavity and bowel.  Likewise, focal areas of mural ischemia can occur 
due to distention and or pressure from the ingesta mass. 
  2.5.1.2 Strangulation Obstruction 
 Occlusion of the intestinal blood flow with simultaneous blockade of the intestinal 
lumen is defined as intestinal strangulation obstruction (Schwartz and Stores, 1969). 
Strangulation obstruction can be further divided into hemorrhagic and ischemic 
strangulation obstruction. Hemorrhagic strangulation obstruction is characterized by 
arteriovenous occlusion and luminal obstruction; however, venous occlusion 
predominates and with some patent arterial blood flow (White, 1990; Snyder JR, 1989). 
This often results in severe mural hemorrhage, edema and eventually necrosis. Clinically, 
this is the most common type of strangulation obstruction in the horse. Ischemic 
strangulation obstruction is characterized by simultaneous venous and arterial occlusion 
together with luminal obstruction.  Despite the type, strangulation obstruction leads to 
rapid injury to the intestinal mucosa, a highly metabolically active layer. Depending on 
the extent of ischemia, strangulation obstruction can also be further classified into warm 
and cold type. In the ‘cold’ type there is a complete blood loss (no flow, as in organ 
transplantation), whereas in the ‘warm’ type there is reduced flow (Southard, 1990). 
 Strangulating large colon volvulus is a common and frequent cause of fatal colic 
requiring surgical intervention (Barclay Foerner, Phillips, 1980; Harrison, 1988; Snyder 
et al., 1989). Approximately 80% of the colon is unanchored and able to move freely in 
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the abdomen; because of this anatomical arrangement, it is prone to volvulus, especially 
at the base of the colon. Unfortunately, the major blood vessels of the colon, the dorsal 
and ventral colonic arteries, enter the mesentery at this location. With the onset of colonic 
volvulus, the twisting and stretching of the vessels in the mesentery compresses the 
vasculature (Fischer and Meagher, 1986), resulting in colonic mucosal ischemic injury 
and epithelial barrier disruption owing to reduced or absent blood flow.  
 Vascular occlusion is commonly associated with large colon volvulus, which 
accounts for 7-40% of horses requiring colic surgery (Barclay, Foerner, Phillips, 1980; 
Huskamp, 1982). If the mucosa is not irreversibly damaged during the volvulus, the 
epithelium may re-establish an intact mucosal barrier through various mechanisms 
(Blikslager et al., 1997). Intestinal strangulation obstruction leads to characteristic lesions 
such as gas and fluid distention, edema, congestion, hemorrhage, necrosis and eventually 
gangrene or rupture (or both) (Van Hoogmoed et al., 2000). The extent of damage varies 
from mild mucosal injury to complete loss of mural wall integrity and subsequent 
endotoxemia, hypovolemia and shock. The magnitude of injury depends on the degree 
and duration of lack of blood supply and the metabolic status of the animal. Despite 
improvement in surgical techniques and post-operative medical care, the survival rate 
after correction of large colon volvulus is low (21-42%) (Fisher and Meagher, 1986).  
 Small intestinal strangulation causes acute, severe colic pain due to intestinal 
ischemia.  Small intestinal strangulation may occur from small intestinal volvulus, 
incarceration through a mesenteric rent or a natural opening such as epiploic foramen or 
inguinal ring. The incidence and frequency of small intestinal strangulation obstruction 
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varies depending on age and other risk factors (Morris, Moore, Ward, 1989). 
2.6 Ischemia-Reperfusion Injury   
 2.6.1 Ischemia  
Ischemia is defined as a critical reduction of blood flow that occurs either due to 
functional constriction or mechanical obstruction of blood vessels (thrombus), leading to 
inadequate tissue perfusion and oxygenation (Fantone, 1990; Grum, 1990). Reduction in 
blood flow causes a reduced oxygen supply to the tissues, resulting in disruption of 
normal cellular and bioenergetic pathways (Fantone, 1990; Grum, 1990). Oxygen is 
essential for normal cellular function and survival. Oxygen deprivation leads to failure of 
oxidative phosphorylation and a decrease in ATP production, which is detrimental to the 
metabolic needs of the tissues. 
 As the oxygen concentration decreases, anaerobic glycolysis occurs in an attempt to 
maintain cell function (Grum, 1990). These changes cause a decreased intracellular pH 
due to the accumulation of lactic acid and hydrogen ions from ATP hydrolysis. The 
accumulated lactic acid further inhibits ATP production and results in increased 
intracellular acidosis. Due to the lack of ATP, the Na+-K+-ATPase pump function is 
altered resulting in increased intracellular calcium concentration. Thus, increased 
intracellular pH, and accumulation of Ca2+ together with the release of proteases, lipases 
and other degrading enzymes results in autolytic destruction of cellular organelles and 
eventually results in cell death (Moore, Muir, Granger, 1995). Thus, a reduction in blood 
supply to the intestinal tract results in rapid injury and death of the highly energy-
dependent mucosal epithelial cells. 
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2.6.2 Reperfusion Injury 
 Reperfusion injury is defined as tissue damage sustained on restoration of blood 
flow after a period of ischemia (Moore, Muir, Granger, 1995). Reperfusion injury occurs 
as a result of a complex series of cellular metabolic events that are initiated during the 
ischemic period and are aggravated during restoration of blood flow. Predominant lesions 
or alterations associated with intestinal I-R injuries include alterations in cell membrane 
permeability, tissue edema, inflammatory cell influx, hemorrhage and necrosis of the 
intestinal wall (Moore et al., 1994). Horses with intestinal compromise from prolonged or 
severe ischemia secondary to strangulation obstruction probably do not undergo a 
relevant reperfusion injury. However, horses with ischemia of less severity or shorter 
duration may be susceptible to reperfusion injury. There is experimental evidence to 
show that the small intestine and large colon of horses are capable of undergoing I-R 
injury (Horne et al., 1994; Moore et al., 1994;). Moore et al. (1994) showed 
histopathologic evidence of reperfusion injury in the large colon of adult horses after 
reestablishment of colonic arterial blood flow after 3 hrs of low-flow ischemia. In horses, 
even after surgical correction of volvulus or strangulation obstruction, horses may 
recover well for a few hours and then begin to deteriorate due to continued ischemia or 
reperfusion injury (Moore et al., 1994).  
Provost et al. (1991) showed that after correction of a 1-hr 720º experimental 
large colon torsion in ponies, colonic blood flow increased above ischemic flow, but 
remained well below the preocclusion flow. Similar observations of reduced blood flow   
below pre-ischemic values after the release of arteriovenous occlusion was shown in the 
large colon of horses (Wilkins et al., 1994). This observed reduction in blood flow after 
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correction of experimentally-induced large colon volvulus (Provost et al., 1991) or 
combined arteriovenous occlusion (Wilkins et al., 1994) in ponies was attributed to 
vasoactive mediators released during obstructive disorders.   
2.6.3 Mechanism of I-R injury 
                               Several mechanisms seem to be essential for the development of post-ischemic 
lesions of the gut. The injury is triggered by both molecular and enzyme-mediated 
mechanisms (Figure 2.4). Initially, oxygen radicals initiated by the hypoxanthine-
xanthine oxidase system are the molecular triggers. Second, activation of phospholipase 
A2, possibly due to influx of calcium, constitutes an enzymatic trigger. This deleterious 
cascade is perpetuated by phospholipids-derived mediators and neutrophils.  
2.6.3.1 Production of Oxygen Free Radicals  
 Under normal conditions, cellular oxidative phosphorylation involves a 4-electron 
reduction of oxygen to water (Flaherty and Weisfeldt, 1988). This occurs as a series of 
reactions resulting in the formation of superoxide anion and hydroxyl radical (OH˙). The 
superoxide anion and OH˙are highly reactive free radicals that can react with cell 
membranes and cause loss of cellular integrity and tissue damage (Flaherty and 
Weisfeldt, 1988). Further, hydrogen peroxide (H2O2), which is not highly reactive, can be 
converted into OH- by ferrous iron, which is made available from the superoxide-
mediated conversion of ferric to ferrous iron (Flaherty and Weisfeldt, 1988). Naturally 
occurring antioxidants protect the tissues from the oxygen free radicals (OFRs) formed 
during normal cellular metabolism. Endogenous antioxidants include enzymatic 
antioxidants (superoxide dismutase, catalase and glutathione peroxidase) and non-
enzymatic antioxidants (alpha-tocopherol, ascorbate and beta-carotene).   
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 During reoxgyenation of ischemic tissues, rapid formation of these radicals can 
overwhelm the protective effects of endogenous antioxidants, resulting in further injury. 
During ischemia, several events occur that set the stage for OFR production upon 
reperfusion. Hypoxanthine accumulates in endothelial cells and in intestinal mucosal 
cells and is catalyzed by xanthine oxidase (XO), an enzyme present in the cytosol, to 
form xanthine and uric acid, with the generation of a superoxide radical. Increased 
intracellular Ca2+ during ischemia, in conjunction with calpain, converts xanthine 
dehydrogenase (XDH) to XO (Cohen, 1989). The hypoxanthine that accumulates during 
ischemia provides large amounts of substrate for superoxide synthesis during 
reoxygenation. Superoxide radicals are converted to H2O2 by endogenous superoxide 
dismutase. 
 The synthesis of OH radicals through iron-dependent mechanisms is called the 
Haber-Weiss reaction (O2.  + H2O2.  → OH·). During reoxygenation, the production of 
free radicals such as OH overwhelms the endogenous antioxidant systems. These 
hydroxyl radicals initiate cellular damage via lipoperoxidation and release of 
phospholipids-derived mediators (leukotriene-B4 and platelet activating factor), which 
are chemoattractants of neutrophils. Thus the overabundance of OFRs produced during 
reperfusion leads to oxidant-induced tissue injury (Flaherty and Weisfeldt, 1988).  
2.6.4 Mucosal Injury 
 Studies have shown strangulation obstruction in adult horses can induce gross 
changes in the intestinal wall, necrosis of villus tips in strangulated small intestinal 
segment, and to a lesser degree, in the non-strangulated jejunum orad to the strangulation  






Figure 2.4 Proposed etiopathogensis of ischemia-reperfusion injury. During ischemia, 
hypothanthine accumulates in epithelial cells and intestinal mucosal cells simultaneous 
with the conversion of xanthine dehydrogenase (XDH) to xanthine oxidase (XO). On 
reperfusion, hypoxanthine is metabolized by XO. The superoxide and hydrogen peroxide 
(H2O2) react in the presence of an Fe3+ catalyst to form the hydroxyl ion (OH-), which 
initiates lipoperoxidation, and causes release of phospholipid-derived mediators (LTB4, 
PAF), which are chemoattractants of neutrophils. On adhesion to the endothelium, 
neutrophils release elastase and lactoferrin, causing extravasation. O2 is converted to O2-, 
which is further metabolized to H2O2 by nicotinamide adenine nucleotide phosphate 
(NADPH) oxidase. Myeloperoxidase then catalyzes the reaction of H2O2 and a chloride 
ion resulting in toxic hypochlorous acid (HOCl). [Redrawn with the permission of Moore 






accumulation of fluid in the intestinal wall, lumen and mesentery and the serosa becomes 
dark purple (Snyder et al., 1988). The thickening of the intestinal wall is due to 
hemorrhage, edema and congestion (Snyder et al., 1989). The observed changes are 
attributed to increased capillary hydrostatic pressure associated with venous obstruction 
and increased microvascular permeability due to inflammatory cell infiltration and 
mediator release during ischemia.  
During small intestinal hemorrhagic strangulation obstruction, fluid sequesters in 
the subepithelial space, and the epithelium separates from the underlying attachment to 
the basement membrane at the villus tip (White, Moore, Trim, 1980). Sloughing of 
epithelial cells develops due to severe intracellular alterations. The villi are completely 
denuded in 3 hrs, and the villi contract to the levels of the crypts (Freeman et al., 1988). 
During various periods of ischemia, complete necrosis of the mucosal epithelium extends 
to the base of the crypt, which occurs by 4 to 5 hrs, and by 6 to 7 hrs degeneration 
extends beyond the muscular layer (White, Moore, Trim, 1980). Combined ischemia and 
reperfusion of 2-hrs duration induces moderately severe mucosal injury in the equine 
jejunum, characterized principally by disruption of enterocyte attachment from the 
basement membrane to the lamina propria (Arden et al., 1990). Eventually, the 
progression of mucosal epithelial injury leads to mucosal necrosis, with disruption of the 
mucosal barrier, allowing migration of luminal bacteria and endotoxin into the systemic 
circulation.  
2.7 Role of ET-1 in the Pathophysiology of The Gastrointestinal Tract Disorders 
 The role of ET-1 in etiopathogensis of various disorders such as ischemia, I-R 
injury, vasospasm, motility disorders and endotoxic shock is well documented in several 
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species (Murch et al., 1992; Chou et al., 1995; Wanecek et al., 1997; Soda et al., 1999; 
Tekin et al., 1999; Ozel et al., 2001). High concentrations of circulating plasma ET-1 
concentrations and increased tissue ET-1 expression have been shown in these 
pathological conditions, suggesting a direct or indirect role of ET in the pathogenesis of 
these disorders. The observed increase in plasma ET-1 is believed to be exacerbated by 
the reduced intestinal blood flow caused by increased vascular resistance, resulting in 
ischemia and I-R injury.  
 Endothelial damage occurs in the colonic vasculature of the large colon and small 
intestine of horses subsequent to I-R and is further injured by endotoxemia (Henninger et 
al., 1992; Dabareiner et al., 1993). The sustained reduction in blood flow and/or 
reperfusion injury may be attributable to the release of endothelial-derived contractile 
factors (EDCF), such as ET-1, from the damaged vasculature or due to imbalance 
between ET-1 and NO release.  
 Horses with strangulation obstruction (low-flow states) and endotoxemia have 
increased levels of circulating IL-1, catecholamines, TNF-α and thrombin, which are 
known to cause increased ET-1 synthesis and secretion (Barton and Callatos, 1999; 
Morris, 1991). The potent contractile effects of exogenous ET-1 were characterized in 
isolated, endothelium-intact and-denuded colonic blood vessels of horses (Venugopal et 
al., 2001). This dose-dependent contraction of colonic vasculature was abolished by prior 
administration of ET receptor antagonists. Thus, the observed reduction in blood flow 
and I-R injury associated with surgical correction in intestinal strangulation obstruction in 
horses may be due to increased circulating levels of ET-1, altering vasomotor tone and 
reducing blood flow.  
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 Endothelin-1 promotes leukocyte rolling, expression of adhesion molecules, platelet 
aggregation, thromboxane formation, superoxide generation and arachidonic acid release 
(Boros et al., 1998). In rats, ET-1 induces a dose-dependent increase in vascular 
permeability through the activation of ETA receptors due to disruption of the endothelial 
barrier (Filep et al., 1991). Use of ET receptor antagonists decreased ET-induced 
endothelial-leukocyte interactions and other pro-inflammatory responses (Boros et al., 
1998). Wolfard et al. (1999) found that ETA receptor antagonism attenuated small bowel 
injury due to I-R in dogs. This clearly suggests that activation of ET receptors is a major 
factor in the mediation of ischemia and I-R injury. Another possibility is that ET-1 
induced vasoconstriction leads to the no-reflow phenomenon or post-ischemic 
hypoperfusion.  
Endothelin immunoreactivity is over-expressed or up-regulated with various 
inflammatory conditions, low-oxygen tension, hypoxia, and peritonitis (Murch et al., 
1992; Dikranian et al., 1994; Chou et al., 1995). Hypoxia induces an increase in ET-1 
immunoreactivity in large intestinal endothelial and epithelial cells of rats (Dikranian et 
al., 1994; Chou et al., 1995). The ET-1 immunolabelling was identified as single particles 
in normoxic rat large intestine, but only in low levels; this labelling was predominantly 
confined to the cytoplasm of endothelial cells of mucosal arterioles and post-capillary 
venules. Hypoxia was associated with increased ET-1 immunolabelling in the mucosal 
vasculature and epithelium of the rat large intestine. 
 Endothelin also has potent contractile activity in non-vascular smooth muscle 
such as vas deferens, uterus, trachea, stomach and ileum of various species (Takahashi et 
al., 1990; Rae, Calixto, D’Orleans-Juste, 1995). Abundant ET-1 binding sites have been 
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found in the stomach, intestine and colon of rats, and other species (Takahashi et al., 
1990; Koseki et al., 1989). All three endothelin isoforms (ET-1, -2 and -3) and both 
receptor types (ETA and ETB) are expressed throughout the gastrointestinal tract, where 
they likely have some physiological role. The ET-1 action mediated by the ETA receptor 
unmasks the inhibitory ET-1 action mediated through the ETB receptor. Repetitive 
peristalsis in fluid-perfused isolated segments of guinea pig small intestine showed that 
propulsive motility is mediated by ETA receptors on enteric neurons, whereas its action is 
masked by activation of ETB receptors (Shahbazian and Holzer, 2000).  
  Several studies suggest ET-1 as a potential candidate in the pathophysiology of 
strangulation obstruction and other disorders. Endothelin-1 is synthesized in the vascular 
endothelium (Yanagisawa et al., 1988) and causes contraction of intestinal vasculature in 
horses (Venugopal et al., 2001). Furthermore, ET receptors are present in both vascular 
and non-vascular smooth muscle of the gastrointestinal tract in horses and other species. 
Although it is highly unlikely that ET-1 alone can induce intestinal damage, it may act 
synergistically with other endogenous mediators in the pathogenesis of gastrointestinal 
tract disorders. Overall, its potent vasoconstrictor nature, widespread distribution and 
synthesis in various organs, its regulatory role with NO in regulating blood flow and 
vasomotor tone, and interrelationships with inflammatory mediators suggest its potential 
involvement in these disorders. 
2.8 Methods of Quantification of Equine Endothelin-1  
Measurement of plasma or tissue expression of ET-1 has been achieved by 
various techniques such as radioimmunoassay (RIA), enzyme-linked immunosorbent 
assay (ELISA), competitive polymerase chain reaction and by real time polymerase chain 
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reaction (TaqMan assay) (Benamou et al., 1998; Uchide et al., 2000; Seligman et al., 
2000). Even though most techniques have advantages and disadvantages, the 
quantification of ET-1 poses a unique problem, due to its inherent nature and its mode of 
secretion into the circulation. Further, numerous problems are associated with 
measurement and interpretation of the measured ET-1, which can be due to either ET-1 
itself and/or the techniques used.  
Circulating concentrations of ET-1 are only a few pg/mL and any assay designed 
to measure the ET-1 must be quiet sensitive. The circulating half-life of ET-1 is 5-7 min 
and it is rapidly cleared mainly through the lungs and kidneys. This depends on a variety 
of factors such as renal or lung function, enzymatic degradation and the binding 
properties of the circulating ET. Further, secretion of ET-1 is mostly abluminal (>80%) 
so the measured plasma ET-1 simply reflects its synthesis and overspill. Commercially, 
there is no anti-equine ET antibody or sera available for the measurement of ET-1. 
Endothelin is highly conserved among mammalian species and a high (>80%) degree of 
homology at the nucleotide level among different species, including bovine, rat, human 
and pig. The ET-1 is the most important and active isoform in blood and is usually the 
one measured. Cross-reactivity of ET-1 to ET-2 and ET-3 should be taken into 
consideration while quantifying the plasma ET-1. Thus, there are a myriad of factors 
involved in the measurement and interpretation of circulating ET levels.   
2.8.1 Immunoassays 
Measurement techniques such as RIA and ELISA are widely employed. Because 
the circulating levels of ET are quite low, the plasma needs to be concentrated or 
extracted before these assays. The extracting process might degrade the ET-1 and also the 
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variation between and within assay may vary depending upon the technique and the 
personnel involved (Morganti et al., 2000). The sensitivity of these assays should also be 
considered. Even though most of the good immunoassays are sufficient to detect levels of 
0.5 pg/mL, the sensitivity of the methods varies and usually falls in the range of 2-8 
pg/mL (Goddard and Webb, 2000). The inter- and intra-assay variation are high, with 
>10% having been reported, reducing the accuracy of the measurement (Morganti et al., 
2000). In addition, sampling and type of sample (icteric, lipemic or hemolyzed) have also 
been found to affect the measurement of the ET-1. Regardless of these problems, the RIA 
is widely employed with careful interpretation and using more appropriate terms like 
‘ET-like immunoreactivity’.  
2.8.2 Polymerase Chain Reaction 
 Polymerase chain reaction (PCR) is a powerful tool for amplifying specific DNA or 
RNA targets. Apart from cloning and sequencing DNA, PCR is used in a variety of 
scientific applications. The exquisite sensitivity and specificity of the PCR reaction (it 
can detect and amplify even one DNA molecule) renders it a unique and valuable 
diagnostic tool in medicine. Various procedures such as quantitative PCR and southern 
blots are used to quantify the PCR products. However, these methods are cumbersome 
and labor intensive. Recently, techniques such as life cycler and TaqMan assays have 
been used.  
2.9 Statement of Hypotheses and Specific Objectives  
  
2.9.1 Global Hypothesis 
 The major physiologic functions of the intestine are motility, secretion and 
absorption, all of which are directly or indirectly controlled by blood flow. So any 
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impairment in blood flow has a deleterious effect on gastrointestinal tract function. 
Reduction in blood flow due to vasoconstrictor agents seems to be of primary importance 
during various occlusive/non-occlusive disorders in horses. Studies have shown that the 
progressive intestinal damage observed in colic during both pre- and post-operative 
conditions could be due to increased levels of vasoconstrictor mediators, resulting in a 
sustained reduction of blood flow. I hypothesize that this sustained reduction in intestinal 
blood flow contributes to intestinal tract injury and is due to increased circulating levels 
of ET-1 and that there will be increased ET-1 immunostaining in horses with intestinal 
strangulation obstruction, compared with gastrointestinal segments from normal horses. 
We also hypothesize that ET-1 will cause a concentration-dependent contraction of the 
cecal smooth muscle of healthy horses. Our studies also included the identification of ET-
1 gene expression and immunohistochemical localization and distribution of ET-1 in the 
gastrointestinal tract of clinically healthy horse and those with naturally acquired 
intestinal strangulation obstruction. Additionally we characterized ET-1 response in the 
equine gastrointestinal smooth muscle mediated by ETA and ETB receptors.   
2.9.2 Specific Objectives 
1. To determine basal circulating plasma ET-like immunoreactivity in healthy 
horses. 
2. To determine circulating plasma ET-like immunoreactivity in horses with 
naturally acquired gastrointestinal tract disorders. 
3. To investigate any relationship between circulating concentrations of plasma ET-
like immunoreactivity and clinical and clincopathological variables and survival 
of horses affected with naturally acquired gastrointestinal tract disorders.  
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4.  To evaluate the presence and regional distribution of ET-1 like immunoreactivity 
in various intestinal segments of healthy horses.  
5. To determine and compare the alterations in intensity and distribution of ET-like 
immunoreactivity in the intestinal segments collected from horses with naturally 
acquired small intestinal and large colon strangulating obstruction with those from 
healthy horses. 
6. To identify the presence of the ET-1 gene expression in various segments of 
gastrointestinal tract of healthy horses and those with naturally acquired intestinal 
strangulation obstruction. 
7. To determine the concentration-response relationship of ET-1 on cecal smooth 
muscle and compare the responses with carbachol, a muscarinic agonist.   
8. To determine ET receptor types involved in the ET-1 mediated smooth muscle 
response in cecal smooth muscle by using specific ET receptor antagonists. 
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Gastrointestinal tract disease (colic) is the leading cause of death in adult horses 
(Baker and Ellis, 1981). Although mortality rates vary among studies, a substantial number 
of horses with large-colon strangulating obstruction failed to survive despite advances in 
equine medicine and surgery (Phillips and Walmsley, 1993). Colonic blood flow remains 
significantly less than baseline values for at least 4 hours after correction of experimentally-
induced complete arteriovenous occlusion of the large colon in ponies (Wilkins et al., 1994). 
Sustained reduction of intestinal blood flow after surgical correction is postulated as a cause 
for the progression of mucosal injury resulting from a continuation of ischemic injury 
associated with microvascular thromboses, splanchnic vasoconstriction or the resulting 
cascade of events related to restoration of blood flow (Moore, 1997). 
Endothelium synthesizes and releases vasorelaxing (eg, nitric oxide [NO], 
prostacyclin) and vasoconstricting (eg, endothelin [ET], prostaglandins) substances that 
regulate vasomotor tone (Katusic and Shepherd, 1991; Shepherd and Katusic, 1991). Several 
intrinsic vasoregulatory mechanisms control tissue blood flow. Reduced blood flow after the 
correction of colonic volvulus could occur secondary to the generation of endogenous 
vasoconstrictor substances that induce contraction of the colonic vascular smooth muscle. 
Thus, sustained hypoperfusion may be mediated by a disruption in the balance between 
endothelium-derived vasoactive substances. For example, a decrease in nitric oxide (NO) 
and/or and an increase in ET-1 could lead to increased intestinal vascular resistance (Moore 
et al., 1995; Turk, 1998).   
Endothelins are a family of peptides (ET-1, ET-2, ET-3 and vasoactive intestinal 









to ETA or ETB receptors (Inoue et al., 1989; Saida, Mitsui, Ishida, 1989). Endothelins, the 
most potent vasoconstrictors known, are synthesized in several tissues where they act to 
mediate or modulate vasomotor tone, cell proliferation and hormone synthesis (Levin, 1995). 
Production of ET-1 by endothelial cells increases during periods of reduced blood flow and 
hypoxia in canine vascular endothelium (Rubanyi and Polokoff, 1994). In addition, 
circulating concentrations of ET increase in several species during certain pathological 
conditions such as endotoxemia, cardiogenic shock, and asthma (Myhre et al., 1993; Takao 
et al., 1994; Cernacek and Stewart, 1989). The sustained hypoperfusion reported after 
arteriovenous occlusion of the large colon in horses (Moore, 1997) could thus be mediated 
by increased synthesis of ET-1 in the intestinal vasculature.  
We hypothesized that ET, and specifically ET-1, may play a central role in 
regulating regional blood flow in the gastrointestinal tract of horses, particularly during 
pathological conditions such as intestinal strangulation obstruction and low-flow states. 
The purposes of the study reported here were to measure and compare plasma 
concentrations of ET-like immunoreactivity between healthy horses and those with 
naturally acquired gastrointestinal tract disease and to investigate the relationship 
between plasma ET-1 like inmmunoreactivity concentrations and clinical and clinico-
pathologic variables and survival in affected horses. 
3.2 Materials and Methods 
3.2.1 Animals  
This study was approved by the Clinical Animal Care and Use Committee of 
Louisiana State University. Horses of various light breeds ranging in age from 1 to 24 years 









basis of medical history and results of a thorough physical examination and clinical 
evaluation. Affected horses (n=142) were those admitted to the Veterinary Teaching 
Hospital at Louisiana State University because of gastrointestinal tract disorders. The 
magnitude and cause of abdominal pain in affected horses was assessed by a thorough 
physical examination and clinical evaluation. Temperature, respiratory rate, heart rate, 
capillary refill time, mucous membrane color, and degree and duration of signs of abdominal 
pain were recorded. For the purposes of this study, we categorized all horses into 1 of 10 
groups. Group 1 (n = 29) comprised the healthy control horses. Group 2 (n = 6) consisted of 
horses with a large intestinal strangulation obstruction (ie, large-colon volvulus and 
cecocolic intussusceptions). Group 3 (n = 26) comprised affected horses with simple 
obstruction of the large intestine (ie, impactions, cecal and colon displacements, 
enterolithiasis). Group 4 (n = 12) comprised horses with a small-intestinal strangulating 
obstruction. Group 5 (n = 9) comprised horses with a simple obstruction of the small 
intestine (ie, ileal impaction). Group 6 (n = 12) and 7 (n = 8) consisted of horses with large 
and small intestinal inflammatory bowl disease, respectively (ie, enterocolitis and anterior 
enteritis, respectively). Group 8 (n = 13) consisted of horses with peritonitis, gastric rupture 
or cecal perforation), Group 9 (n= 11) consisted of horses with gastric disorders  (ie, ulcers, 
impactions), and Group 10 ( n =45) consisted of horses with idiopathic gastrointestinal tract 
disorders (ie, tympany or undiagnosed medical colic). Affected horses were assigned to a 
group on the basis of the clinical diagnosis made from the results of clinical, 
clinicopathologic, and where applicable, surgical and postmortem examinations.  
3.2.2 Sample Collection 









admission to the Veterinary Teaching Hospital and prior to the initiation of treatment.  Blood 
(10 ml) was collected via jugular venipuncture into prechilled collection tubes containing 
EDTAa (500 kU/ml) and aprotininb (1 mg/ml).  Samples were kept cold and centrifuged 
within a few minutes of collection at 1,500 X g for 10 in a refrigerated (4˚C) centrifuge. 
Plasma was then transferred into plastic tubes and stored at –70˚C until assayed. Additional 
blood samples (3 ml) were collected into tubes containing EDTA for determination of CBC 
and plasma fibrinogen determination and into tubes containing heparin for plasma 
biochemistry analyses, including determination of creatinine concentration.  
3.2.3 Measurement of Plasma ET-Like Immunoreactivity 
Plasma ET-like immunoreactivity was quantified by use of a radioimmunoassayc 
designed to measure ET-1 concentration in human plasma. The antibody used in this assay 
principally recognizes human ET-1. However, the manufacturer reports that the antibody has 
67 and 84 % cross-reactivity with human ET-2 and ET-3, respectively. Before assaying 
plasma samples collected from control and affected horses, the assay was validated for use 
with equine plasma. Recovery of ET-like immunoreactivity was determined by adding 
known amounts of synthetic human ET-1 to pooled plasma from clinically normal horses. 
Concentrations of ET in multiple replicates of spiked samples were measured within and 
between assays to determine intra-and interassay variations, respectively.  
 To prepare plasma samples for the assay, they were thawed and extracted according 
to the manufacturer’s recommended protocol by use of reverse-phase columns.d Prior to 
extraction, columns were activated with 5 ml of 100% methanol, washed with 5 ml of 
deionized water, and pre-treated with 5 ml of 4% acetic acid in distilled water; plasma 









After the addition of acidified plasma samples (1.5 ml) to pretreated columns, columns were 
washed with 25% ethanol in distilled water, and ET was eluted with 4% acetic acid in a 
solution of 86% ethanol in distilled water. The eluant was evaporated to complete dryness in 
a 37˚C water bath under a stream of clean, dry nitrogen gas. Dried extracts were 
reconstituted in 0.5 ml of assay buffer (borate buffer, pH 8.4). 
Standard curves for the radioimmunoassay were prepared by the use of synthetic 
human ET-1 according to the manufacturer’s guidelines. Each standard and extracted sample 
was assayed in duplicate. Rabbit 125I –labeled ET-1 tracer and rabbit anti-endothelin 
antiserum were added to each extracted sample and incubated for 18 hrs at 4˚C. A donkey 
anti-rabbit cellulose precipitant was added to each tube and was incubated at room 
temperature (20 to 22˚C) for 30 minutes.  Tubes were then centrifuged at 2,000 X g for 15 
minutes. The supernatant containing unbound 125I-labeled ET-1 was separated from the 
pellet (containing antibody-bound 125I-labeled ET-1) by vacuum aspiration. Radioactivity in 
the pellet was counted in a gamma counter for 2 minutes. Concentrations of ET-like 
immunoreactivity in extracted plasma samples were determined by extrapolation from a 
cubic spline standard curve. 
3.2.4 Statistical Analyses 
 Continuous variables considered in the statistical analyses included plasma 
concentrations of ET-like immunoreactivity, heart rate, total plasma protein and creatinine 
concentration, PCV, platelet and neutrophil counts, WBC, durations of signs of pain, and 
outcome (ie, survival vs nonsurvival). Continuous data were summarized by the use of 
median, mean (± SD), and range. 









determined by failure to reject the null hypothesis at P < 0.05.  Many variables did not 
follow a normal distribution.  Thus, continuous data were compared between control and 
affected horses by use of the Kruskall-Wallis test for comparison of multiple groups of 
ranked data. When a significant difference (P < 0.05) was detected, selected ad hoc 
comparisons were made by the use of the Kruskall-Wallis procedure and by correcting 
the significance level for the number of comparisons to maintain a type I error at 0.05.  
For affected horses, an association between ET-like immunoreactivity and other 
continuous variables was explored by use of stepwise linear regression. Variables were 
maintained in the regression equation at P < 0.05.  Pearson’s correlation coefficients 
were calculated for the variables in the model. In addition, associations between survival 
and both the continuous variables and the categorical groupings were explored by use of 
logistic regression. Any horse that died or was euthanatized after a diagnosis was made 
was assigned to the nonsurvival group.  Stepwise selection of variables was performed, 
with variables maintained in the model if the Wald statistic was significant at P < 0.05.  
The 95% confidence interval (CI) of the conditional odds ratio for the variables included 
in the model was calculated, and variables whose CI excluded 1 were considered 
significant. All analyses were performed with the use of computer software programs.e  
3.3 Results  
3.3.1 Validation Assay    
 Mean percentage recovery of ET-1 recovered was 80% (range, 64 to 102%). Inter-
assay and intra-assay variation were < 5% and 10%, respectively. The lowest detectable limit 










3.3.2 Plasma Concentrations of ET-Like Immunoreactivity  
 Median plasma concentrations of ET-like immunoreactivity were significantly 
greater in horses with various gastrointestinal tract disorders, compared with healthy horses 
(Table 3.1). In affected horses, the greatest median values for the ET-like immunoreactivity 
were observed for horses with large intestinal strangulating obstruction (median, 10.02 
pg/ml; rang, 3.8 to 22.62 pg/ml), peritonitis (9.19 pg/ml, 7.9 to 25.83 pg/ml), and 
enterocolitis (8.89 pg/ml, 6.30 to 18.36 pg/ml). 
3.3.3 Results of Clinical, Hematologic, and Biochemical Analyses  
 Packed cell volume (PCV), platelet count, heart rate, and plasma creatinine 
concentration were slightly greater, and WBC and neutrophil count were slightly lower in 
affected horses, compared with healthy horses (P>0.05). However, none of these differences 
were statistically significant. In addition, none of the other clinical, hematologic, or 
biochemical variables differed significantly between healthy and affected horses.   
3.3.4 Association Between Plasma ET-Like Immunoreactivity and PCV and 
Duration of Signs of Pain   
 
 Considering results from all affected horses, a significant association was found 
between the plasma concentration of ET-like immunoreactivity and PCV and duration of 
signs of pain (Figures 3.1 and 3.2). However, when these variables were considered 
separately, the positive correlation was only modest (PCV, r =0.344; duration of signs of 
pain, r = 0.216). Correlation increased when both PCV and duration of pain were added 
to the regression model (r = 0.407). No other variables were significantly associated with 












Table 3.1 Plasma concentrations of endothelin-(ET)- like immunoreactivity in healthy 
horses and horses with naturally acquired gastrointestinal tract disorders.  
 
 
                     Group (n)                                              ET-like immunoreactivity (pg/ml)  
                                                                                    _____________________________ 
                                                                                           Median              Range  
 
Healthy (29)                                                                          1.8a                      1.09-3.12 
LI strangulating obstruction (6)                                           10.02c                  3.8-22.62 
LI simple obstruction (26)                                                    3.97bc                 3.27-8.01 
SI strangulating obstruction (12)                                          5.53bcd               1.72-9.48 
SI simple obstruction (9)                                                      6.14bcd               4.97-9.70 
  
Enterocolitis (12)                                                                 8.89bcd               6.30-18.36 
Anterior enteritis (8)                                                            3.29bc                 1.06-7.23 
Peritonitis (13)                                                                     9.19cd                 7.89-25.83 
Gastric disorders (11)                                                          4.72bd                 3.51-7.20 
Idiopathic colic (45)                                                             6.24bc                3.62-9.67 
 
 
LI = Large intestinal. SI = Small intestinal 









































Figure 3.1 Packed cell volume versus plasma concentrations of endothelin- (ET)-like 
immunoreactivity in 142 horses with naturally acquired gastrointestinal tract disorders. 
The association between the 2 variables was significant (P <0.01), but the variables were 




































                       
Figure 3.2 Duration of signs of abdominal pain versus plasma concentrations of endothelin-
(ET)-like immunoreactivity in 142 horses with naturally acquired gastrointestinal tract 
disorders. The association between the 2 variables was significant (P < 0.01), but the 





















3.3.5 Association Between Outcome, ET-Like Immunoreactivity and PCV  
 Logistic regression analysis revealed a significant association between outcome 
(survival vs non-survival) and plasma concentration of ET-like immunoreactivity (odds 
ratio, 0.942; 95% CI, 0.890 to 0.998) and PCV (0.945, 0.896 to 0.996) (Figure 3.3). 
Survival was best explained by addition of both variables (ET-like immunoreactivity and 
PCV) to the logistic model. No other variables were significantly associated with 
outcome.    
3.4 Discussion 
 Results of our study indicate that the circulating concentration of ET-like 
immunoreactivity is increased in horses with gastrointestinal tract disorders, compared with 
healthy horses. Plasma ET-like immunoreactivity in 29 healthy horses ranged from 1.09 to 
3.2 pg/ml, which is in agreement with values reported previously for horses (Benamou, et al., 
1998). Within the affected group, median plasma concentration of ET-like immunoreactivity 
was greatest in horses with large intestinal strangulating obstruction, enterocolitis, and 
peritonitis. Logistic regression analysis revealed an association between the ET-like 
immunoreactivity and outcome, whereas regression analysis revealed an association between 
plasma ET-like immunoreactivity, PCV, and duration of signs of pain. 
 Two ET receptors have been identified and cloned: ETA receptors on the vascular 
smooth muscle mediate vasoconstriction, and a subtype of the ETB (ETB2) receptors located 
on the endothelium mediate vasodilatation via release of prostacyclin or NO (Clozel et al., 
1992).  The expression of the ET family of vasoactive peptides increases in different tissues 
such as intestine and heart of rats, humans, and dogs during low-flow ischemia, increased 



































Figure 3.3 - Logistic regression analysis showed a significant association between outcome 
(survival vs non-survival) and plasma concentration of ET-like immunoreactivity (odds 
ratio, 0.942; 95% CI, 0.890 to 0.998) and PCV (0.945, 0.896 to 0.996). Survival was best 

















and Vanhoutte, 1986).  Endothelin-1 is believed to be the most important isoform, although 
all isoforms have been identified in the intestine of people and mice (Inoue et al., 1989; 
Saida, Mitsui, Ishida, 1989). Moreover, there is a growing body of evidence that ET-1 serves 
as a principal mediator in pathophysiological events involving ischemia-reperfusion (I-R) 
injury associated with intestinal strangulation obstruction and myocardial infarction in pigs 
and human patients (Battistini and Dussault, 1998; Fevang et al., 1998).  Because of the 
reported cross-reactivity of the anti-ET-1 antibody used in the radioimmuonoassay with ET-
2 and ET-3, we could not specifically determine which ET isoform was present in the plasma 
samples collected from affected and control horses. However, we presumed that the 
immunoreactivity detected was primarily attributable to ET-1 because this is not only the 
predominant isoform in the intestine of many animal species but it is also the circulating 
isoform found during various pathologic conditions in several species (Fevang et al, 1998; 
Weitzberg et al., 1991).  
 Because of its high metabolic activity and substantial blood flow requirements, the 
gastrointestinal mucosa is the primary target tissue of many types of low-flow induced 
circulatory shock associated with intestinal obstruction, hemorrhage and sepsis (Fevang et al, 
1998; Weitzberg et al., 1991; Massberg et al., 1998) Occlusive vascular diseases and non-
occlusive states associated with I-R lead to endothelial synthesis of ET (Rubanyi and 
Polokoff, 1994). Increased intestinal vascular resistance during circulatory shock shunts 
blood away from gastrointestinal tissues to more vital organs (Patel, Kaleya, Sammartaon, 
1992), resulting in intestinal hypoperfusion. Increased plasma concentrations of ET-1 in pigs 
with an intestinal strangulation obstruction may be associated with reduced intestinal blood 









derived vasorelaxant, inhibits the reduction ET synthesis (Boulanger and Luscher, 1990).  
Further, during I-R injury and other low-flow states, endothelial production of NO is 
compromised and responsiveness to ET-1 is enhanced (Thompson, Valeri, Lieberthal, 1995; 
Wood et al., 1995). Thus, disruption of the balance between ET-1 and NO may lead to 
prolonged vasoconstriction, resulting in impaired intestinal blood flow, ischemic injury and 
ultimately mucosal barrier disruption.  
 Greater than 80% of the ET-1 synthesized by the endothelium is secreted 
abluminally toward the tunica media where it functions in a paracrine fashion (Wagner et al., 
1992). Therefore, measurement of plasma ET-1 concentrations may not truly reflect the 
overall synthesis and release of ET-1 during pathophysiologic events. Despite these 
limitations, measurement of plasma ET-1 concentrations reportedly is a useful indicator of 
congestive heart failure, pulmonary hypertension and endotoxemia in humans and other 
animals (Nakamura et al., 1991; Lerman et al., 1991; Cody et al., 1992).  The increase in 
plasma concentrations of ET-like immunoreactivity that we detected in horses with 
gastrointestinal tract disorders supports similar findings in pigs with strangulation 
obstruction (Fevang et al., 1998). In addition, ET-1 mRNA expression was shown to be 
increased in the small intestine of rats with peritonitis (Chou et al., 1995).  Although we 
detected significantly more plasma ET-like immunoreactivity in horses with gastrointestinal 
tract disorders, compared with healthy horses, we could not determine whether this increase 
was reflected solely by an increase in ET-1 or whether this increase was specific to horses 
with colic. The increase in circulating ET-like immunoreactivity could have been attributable 
to other factors related or unrelated to the primary disease.  









in affected horses may have resulted from specific stimuli leading to increased synthesis and 
release of ET-1 from the vasculature of the affected intestinal segment or from the affected 
gastrointestinal tract tissues. Shock-related stimuli may have also induced an increase in ET-
1 synthesis from tissues distant to the gastrointestinal tract. Alternatively, an increase in 
concentration of circulating ET-1 may have simply resulted from hemoconcentration.   
Lipopolysaccharides, tumor necrosis factor (TNF), and interleukin-1 (IL-1) are principal 
mediators of sepsis and are also important modulators of ET-1 secretion (Battistini, Forget, 
Laight, 1996; Dinarello, 1991). These and other regulatory peptides may activate the ET-1 
gene through an acute phase response element of an upstream regulatory element (Marsden 
and Brenner, 1992). In vitro ET-1 synthesis increases in cultured porcine aortic endothelial 
cells stimulated with TNF and IL-1 (Kanse et al., 1991; Yoshizumi et al., 1990).  Although 
speculative, increased plasma concentrations of ET-like immunoreactivity that we detected 
in affected horses may have resulted from endothelial injury or colic-associated stimuli 
(interleukins or TNF) that lead to an increased release of ET-1 from the intestinal vascular 
endothelium and subsequent spillover into the systemic circulation. However, the exact 
mechanism for the increase in plasma ET-like immunoreactivity in horses with 
gastrointestinal tract disorders could not be determined. 
   Median plasma concentration of ET-like immunoreactivity in horses was greatest in 
horses with large intestinal strangulation obstructions, enterocolitis, and peritonitis. 
Clinically, the magnitude of tissue damage and severity of shock are typically more severe in 
horses with these conditions, compared with other causes of colic. In horses with obstructive 
pulmonary disease, bronchoalveolar lavage fluid ET-1 concentrations were strongly 









concentrations of ET-like immunoreactivity in horses with the large-intestinal strangulating 
obstruction, enterocolitis, and peritonitis, may also correlate with the severity of endothelial 
damage and tissue injury, and may indicate involvement of ET-1 in the etiopathogenesis of 
these disorders.  Alternatively, high ET-like immunoreactivity concentrations may have 
simply reflect a more severe systemic illness in these horses. In rats, administration of ET-1 
leads to hemoconcentration, edema, and enhanced protein extravasations in various organs 
including the duodenum (Valentin et al., 1991). In our study, the significant association 
between plasma ET-like immunoreactivity concentration and PCV and the duration of signs 
of pain may have been attributable to severe and long-standing disease that resulted in a 
greater synthesis and release of ET-1. However, the increase in plasma ET-like 
immunoreactivity concentration may also have been associated with the degree of 
dehydration and altered cardiovascular status of the horses with severe gastrointestinal tract 
disease.   
 Circulating concentrations of ET-1 associated with pathologic conditions can 
affect systemic hemodynamics, resulting in increased systemic vascular resistance and 
decreased cardiac output (Lerman et al., 1991). Logistic regression analyses revealed a 
strong positive correlation between the plasma ET-like immunoreactivity concentration 
and outcome (survival vs nonsurvival) in the horses of the present study. Similarly, in 
humans with congestive heart failure, plasma ET concentrations are positively correlated 
with the extent of pulmonary hypertension (Cody et al., 1992). However, from the present 
study, we cannot determine whether the increase in plasma concentration of ET-like 
immunoreactivity simply represents a biological marker for the disease severity, and 









contributes to the etiopathogenesis of these disorders. The use of ET-1 receptor 
antagonists may help clarify the role of ET-1 as a biological marker or pathologic 
mediator of colic in horses.   
3.5 Product Information 
a,b Sigma Chemical Co, St Louis, Mo. 
c Endothelin, Nichols Institute Diagnostics, San Juan Capistrano, Calif. 
dSep-Pak C18 columns, Waters Associates, Milford, Mass. 
eSAS for windows 95, version  7.0, SAS Systems Inc, Cary, NC. 
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DISTRIBUTION OF ENDOTHELIN-1 IMMUNOHISTOCHEMICAL STAINING 
IN THE INTESTINAL TRACT OF CLINICALLY HEALTHY HORSES AND IN 

























The gastrointestinal tract is the major target tissue of low-flow induced circulatory 
shock such as occlusion, volvulus, hemorrhage and or sepsis (Alexander et al., 1990; 
Massberg et al., 1995). Small intestinal and large colon strangulating obstruction account 
for approximately 10% off all horses with colic, and these conditions are universally fatal 
without surgical correction (Phillips and Walmsley, 1993). Despite surgical correction 
and intensive medical care, most horses die due to the rapidity with which the intestinal 
mucosa undergoes irreversible damage during ischemia, and subsequent endotoxemia and 
hypovolemic shock. Increased plasma levels of endothelin-1 (ET-1) have been shown 
during low-flow ischemia of the small intestine in various species like humans, pigs and 
horses (Sharefkin et al., 1991; Fevang et al., 1998; Ramaswamy et al., 2002), suggesting 
involvement of ET-1 in regulation of mucosal hypoperfusion and in the pathogenesis of 
intestinal ischemia.  
Endothelins are a family of vasoconstrictor peptides synthesized by various cells 
that exert numerous biological and pathophysiologic actions via binding to G-linked 
protein receptor subtypes, ETA and ETB (Yanagisawa et al., 1998; Rubanyi and Polokoff, 
1994). All three ET isoforms (ET-1, ET-2 and ET-3) have 21 amino acids and 2 disulfide 
bridges, each with different affinities for the ET receptors (Inoue et al., 1989). Each ET 
isoform is a product of separate genes that encode the large precursor prepro-ET. Of all 
ET isoforms present in the intestine (Matsumoto et al., 1989; Chou et al., 1995; de la 
Monte et al., 1995), ET-1 is suggested as the most important isoform in the regulation of 
intestinal functions.  
 82
Endothelin-like immunoreactivity has been observed in endothelial cells, vascular 
smooth muscle cells, mast cells, epithelial cells and various other cell types in the 
intestinal tract of different species (Eaker et al., 1995; Liu, Yamada, Ochi, 1998; 
Minchenko et al., 1999). In the human colon, ET and its binding sites were observed in 
the enteric neurons, submucosal plexus, mucosal layer and in blood vessel walls (Inagaki 
et al., 1991; Egidy et al., 2000). Expression of ET in vascular and non-vascular cells and 
tissues suggests its diverse role in various physiological functions such as vasomotor 
tone, ion secretion and closure of the ductus arteriosus (Coceani and Kelsey, 2000; Levin, 
1995; Rubanyi and Polokoff, 1994). However, to our knowledge there are no studies 
reported regarding the distribution of ET-1 in the gastrointestinal tract of horses. 
Increased expression of ET-1 and intensity of staining in epithelial and 
endothelial cells of the rat colon were correlated with the degree of mucosal injury 
(Sugimachi et al., 2000). Hypoxia has been shown to induce an increase in ET-1 like 
immunoreactivity in large intestinal endothelial and epithelial cells of rats (Dikranian et 
al., 1994). It has been hypothesized that a sustained reduction in intestinal blood flow and 
progressive mucosal injury after intestinal arteriovenous occlusion in horses could be 
mediated principally by increased local expression and synthesis of ET-1 in the intestinal 
microvasculature and tissues.  
We hypothesized that there would be ET-1 staining in the surface epithelium and 
vasculature of the gastrointestinal tract of normal horses, and this immunohistochemical 
staining would increase in horses with naturally acquired intestinal strangulation 
obstruction. The presence of ET-1 like immunoreactivity in the normal horse will suggest 
its role in normal physiological functions, whereas increased expression of ET-1 in blood 
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vessels and intestinal tissues during strangulation obstruction may indicate its 
involvement in the pathogenesis of these disorders. The objectives of the study were to 
evaluate the regional distribution of ET-1 in different segments of the gastrointestinal 
tract of clinically healthy horses, and to determine and compare the expression of ET-1 
like immunoreactivity in the intestinal segments of horses with naturally acquired small 
intestinal and large colon strangulating obstruction.  
4.2 Materials and Methods 
4.2.1 Tissue Collection 
This study was approved by the Clinical Animal Care and Use Committee of 
Louisiana State University. Gastrointestinal tract biopsy specimens were collected from 6 
clinically healthy adult horses with no history or clinical or laboratory evidence of 
disease involving the gastrointestinal tract or cardiovascular system (control, n =6) 
destined for euthanasia for other reasons. Samples were collected from the control horses 
immediately after euthanasia with an overdose of pentobarbitala (100 mg/kg).  
Sections were collected from the following sites from the gastrointestinal tract of 
control horses: greater curvature of stomach, duodenum (1 foot from pylorus), ileum (1 
foot from ileocecal junction), cecal body (half way between apex and base), right ventral 
colon (1 foot from the cecocolic junction), left ventral colon (1 foot from pelvic flexure), 
left dorsal colon (1 foot from pelvic flexure), right dorsal colon (1 foot from 
diaphragmatic flexure), transverse colon (6 inches from duodenocolic ligament), and the 
small colon (4 feet from duodenocolic ligament). All biopsy specimens were collected 
from the anti-mesenteric side of the intestinal segments from control and affected horses. 
Biopsy specimens were also collected from horses admitted to the LSU Veterinary 
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Teaching Hospital with naturally acquired small intestinal (n=25) and large colon (n=13) 
strangulation obstruction at the time of exploratory surgery or after euthanasia. Tissues 
were fixed in 4% aqueous zinc buffered formalin for approximately 24 hours and 
embedded in paraffin for immunohistochemistry.  
4.2.2 ET-1 Immunohistochemistry 
 Paraffin-embedded tissues were serially sectioned at 4µm and attached to 
silanized slides and dried overnight (37ºC). Tissues sections were deparaffinized, 
hydrated through graded alcohol solutions, and equilibrated in phosphate buffered saline 
(PBS, pH 7.6). Immunostaining was performed, using a modified three-step Avidin-
Biotin complex (ABC) method with a Vector Elite ABC Rabbit IgG kit (Hsu, Raine 
Fanger, 1981). The entire staining procedure was performed at room temperature (20-
22ºC).  
After rehydration, slides were immersed in 0.3% hydrogen peroxide in methanol 
for 30 minutes to block endogenous peroxidase activity. Slides were rinsed and pre-
incubated with normal goat serumb (1:50) for 45 minutes to block non-specific binding. 
After incubation, the excess serum was removed and the primary antibody (Ab), rabbit-
anti-ET-1 antiserac at a dilution of 1:700, was added and incubated at room temperature 
for 60 minutes. After addition of primary Ab, the slides were washed and incubated with 
secondary biotinylated goat anti-rabbit-IgG antisera (1:200) for 30 minutes. The ABC 
mixtured was applied for 30 minutes. The horse-radish-peroxidase substrates were then 
developed by staining with freshly prepared chromogen, diaminobenzidine (DAB), for 5 
minutes. The slides were counterstained with Mayer’s heamatoxylin for 30 sec, 
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dehydrated with ethanol and xylene, cleared and mounted in a resinous media and 
evaluated by light microscopy. Brown staining was considered positive. 
The specificity for ET-1 like immunoreactivity was evaluated: 1) by the omission 
of primary antibody; 2) by the substitution of normal rabbit IgG for primary antibody; 
and 3) by pre-incubation of the primary antibody overnight at room temperature with 
excess ET-1e peptide.  The blocked antibodies were then used on tissue sections and run 
parallel with immunostaining.  
Three sections from each slide were evaluated twice to minimize variation.  A 
numerical value ranging from 0 to 3 was assigned to each slide based on the relative 
amount of staining, with control slides (blocked control). The intensity and distribution of 
the ET-1 like immunoreactivity for the following variables was evaluated: surface 
epithelium, crypt epithelium, mucosal vasculature, submucosal arterioles and venules 
(smooth muscle, endothelium), muscularis and serosa. A zero score was assigned if there 
was no staining present. Grade 1 - indicated a mild increase brown staining compared 
with blocked antibody; Grade 2 - indicated a moderate increase brown staining compared 
with blocked antibody; and Grade 3 - indicated an intense increase in brown staining over 
that with blocked antibody.  
 The affected segments (duodenum, jejunum, ileum, pelvic flexure) of horses 
with small intestinal and large colon strangulating obstruction were compared with the 
duodenum, jejunum, ileum, and pelvic flexure scores from control horses. The modal 





          In healthy horses, the intestinal surface epithelium and large vessels, mainly the 
veins and the muscular layer, were positive for ET-like immunoreactivity (Figures 4.1, 
4.3 and 4.4). No staining was observed in mucosal mucus glands, and Brunner’s glands in 
duodenum and jejunum, respectively (Figure 4.2). The observed ET-like 
immunoreactivity was completely abolished by pre-absorption of antiserum with an 
excess amount of ET-1 (Figure 4.1B and 4.3B). Under high magnification, ET-like 
immunoreactivity was observed in the cytoplasm of the surface epithelial cells and 
endothelial cells with moderate staining intensity. The staining was more intense in the 
apical region of the surface epithelium. The surface epithelial cells also showed a mosaic 
distribution pattern of ET-like immunoreactivity (Figure 4.4). Staining of crypt 
epithelium and endothelial cells were variable and inconsistent. Veins stained more 
intensely than arteries (Fig 4.5). ET-like immunoreactivity was diffuse and variable in the 
endothelium of the blood vessels. The ET-like immunoreactivity staining in muscularis 
was diffuse and variable, with greatest intensity of staining observed in the outer 
muscular and serosal layers.  
 Heavy hemorrhage, congestion and lack of structural details in affected tissue 
segments from horses with naturally acquired intestinal strangulation obstruction made it 
difficult to subjectively evaluate ET-like immunoreactivity. Overall, staining intensity 
was greater in the serosal and outer muscular layers of the affected intestinal segments 
(Figure 4.6). Diffuse staining was also noted in the mucosa and in blood vessels of 
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Figure 4.1 Photomicrograph showing ET-like immunoreactivity staining in the surface 
epithelium of the duodenum of a clinically healthy normal horse (A). The ET-1 


















Figure 4.2 Photomicrograph illustrating the lack of ET-like immunoreactivity in the 
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Figure 4.3 Photomicrograph illustrating intense ET-like immunoreactivity in the surface 
epithelium and lamina propria of the ileum of a clinically healthy horse (A). Pre-


























Figure 4.4 Photomicrograph illustrating patchy distribution of ET-like immunoreactivity 
(arrow heads) with anti-ET-1 Ab staining in the pelvic flexure of clinically healthy horses 
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Figure 4.5 Photomicrograph illustrating intense ET-like immunoreactivity in the tunica 
media and endothelial lining of the blood vessels in a healthy horse (A) and in horse with 

















Figure 4.6 Photomicrograph illustrating diffuse and intense ET-like immunoreactivity in 
the muscular and serosal layer of pelvic flexure of horse with colon torsion. Note the 
























Figure 4.7 Photomicrograph illustrating diffuse ET-like immunoreactivity in the mucosal 









intestinal segments from horses with large colon volvulus, compared with control tissues 
(Figure 4.7). The modal scores for clinically healthy horses varied from 0 and 1 
depending on tissue type and variable (Table 4.1). Overall, the modal (most frequent) 
scores of ET-1 staining intensities were higher (2) compared with the ET-1 
immunoreactivity staining in clinically healthy horses (Table 4.2) 
4.4 Discussion 
The distribution of ET-like immunoreactivity was examined in the gastrointestinal 
tract of healthy horses and in intestinal segments from horses with naturally acquired 
intestinal strangulation obstruction. The most important findings of this study were the 
presence of ET-1 like immunoreactivity in the villi and surface epithelium of the small 
intestine and large intestine, respectively, in healthy horses. This suggests a role for ET-1 
on normal gastrointestinal tract function. The ET-like immunoreactivity was 
predominantly confined to the cytoplasm of the surface epithelium with less staining in 
the crypts, and variable, diffuse ET-like staining in the muscularis layer. A similar pattern 
of ET-immunoreactivity has been reported in rat colon (Sugimachi et al., 2000). The 
endothelial lining of blood vessels in different segments of the gastrointestinal tract 
stained positive for ET-1, suggesting its involvement in the regulation of regional 
intestinal blood flow.  
Localization of ET-1 was investigated using apolyclonal antibody against ET-1 
(rabbit). Due to the cross reactivity of anti-ET-1 antibody used in the study (ET-1-100%; 
ET-2 - 91%; ET-3-0.05%), we could not specifically determine the ET isoforms present 
in the gastrointestinal tract. However, it is mostly ET-1 because of its predominant  
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Table 4.1 Modal values for ET-1 immunoreactivity staining scores in different sections 
















Duodenum (n =5) 
Jejunum (n =5) 
Ileum(n =6) 
Cecum (n =6) 
Pelvic flexure(n =4) 
Right ventral colon(n =6) 
Right dorsal colon (n =5) 
Left ventral colon (n =6) 
Left dorsal colon (n =6) 
Small colon (n =6) 




































































B.V – blood vessels, T. Media – tunica media, SM – smooth muscle 
 
 
Table 4.2 Modal values of ET-1 immunoreactivity staining scores in affected intestinal 
segments from horses with naturally acquired small intestinal and large colon 
strangulation obstruction.  
 







SI strangulation (n =25) 2 2 2 2 2 
LI strangulation (n =13) 2 1 2 1 2 








distribution in the intestinal tract and the fact that ET-like immunoreactivity was 
abolished by pre-absorption of anti-ET-1 with excess amount of ET-1. Endothelins, 21 
amino acid peptides, are present in nearly every organ examined. Of the three isoforms, 
ET-1 and ET-2 were expressed in the gastrointestinal tract (de La Monte et al., 1995); 
and are potent constrictors of intestinal smooth muscle. The ET receptor types (ETA and 
ETB) have been identified in the intestine of pigs, humans and other species and have 
been found to have increased expression in young animals (Nankervis, Dunaway, Miller, 
2001; Egidy et al., 2000). The roles of ET-1 in the regulation of intestinal hemodynamics 
and oxygenation of tissues have been studied (Nankervis, Dunaway, Miller, 2001). The 
presence and identification of ET-1, and its receptor types in the intestinal tissues suggest 
a physiological role of ET-1 in intestinal function.  
The release of ET-1 occurs in discontinuous pulses from the blood vessels and 
helps in maintenance of vasomotor tone. The inconsistent ET-1 staining of endothelial 
cells within different sections of the intestine may thus reflect the state/change in ET-1 
production by the blood vessels. Similar variable staining intensity and the diffuse nature 
of ET-1 staining was observed in previous studies in rat colon (Sugimachi et al., 2000) 
and human placenta (Barros et al., 2001). 
The ET-1 immunolabelling was identified as single particles in normoxic rat large 
intestine, but only in low levels with labeling predominantly confined to the cytoplasm of 
endothelial cells of mucosal arterioles and post-capillary venules (Dikranian et al., 1994). 
The expression of ET-1 like immunoreactivity in the intestinal surface epithelium of the 
horses in this study suggests that ET-1 might play a role in epithelial cell differentiation 
or secretory activity as suggested by others in different species (Takahashi et al., 1990; de 
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la Monte et al., 1995; Shichiri, Marumo, Yukio, 1998). The gastrointestinal tract 
epithelial cells and intestinal vasculature possess ETA and ETB receptors (Inagaki et al., 
1991; Nankervis, Dunaway, Miller, 2001). Therefore, the observed ET-1 like 
immunoreactivity in the villi and surface epithelial cells may reflect a paracrine type of 
uptake of ET secreted by endothelial or lamina proprial cells.  
During shock or low-flow states, ET-1 release likely plays a role in helping to 
shunt blood away from the splanchnic circulation to more vital organs (Fevang et al., 
1998). Although this is a needed defense mechanism, it likely contributes to the 
continued ischemia in the post-operative period, or subsequent to shock resuscitation, and 
could result in mucosal barrier disruption. Further, the functional role of ET-1 in 
gastrointestinal functions like intestinal motility and ion secretion has been elucidated 
(Moummi et al., 1992; Hosokawa et al., 1995). Recently, we reported an increase in 
plasma ET-like immunoreactivity in horses with acquired gastrointestinal tract disorders 
such as large intestinal strangulation obstruction, peritonitis and enterocolitis 
(Ramaswamy et al., 2002). The mechanism of increased plasma ET-1 concentrations in 
various gastrointestinal tract disorders (Murch et al., 1992; Ramaswamy et al., 2002) 
though unclear, is speculated to be an increased synthesis or release of ET-1 by injured or 
stimulated endothelial cells from affected intestinal tissues and subsequent absorption 
into the circulation, rather than the systemic release of ET-1 from other tissues. 
Submucosal injection of ET-1 induces gastric ulceration secondary to a decrease in 
gastric mucosal blood flow, ischemia and increased acid secretion (Watanabe et al., 
2000). 
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 In our study, increased intensity of ET-like immunoreactivity in the outer 
muscular layer and blood vessels of the intestinal segments collected from horses with 
acquired intestinal strangulating obstruction disorders was observed. The increased 
expression of ET-1 may enhance epithelial damage because of its ability to cause 
vascular contraction and ischemia. However, the lack of structural details due to 
advanced disease conditions and variable staining intensity between viable and non-
viable sections of affected tissues makes it difficult to confirm this assumption. 
Involvement of ET-1 in the pathogenesis of various intestinal disorders has been 
previously indicated by immunohistochemistry (Chou et al., 2001; Sugimachi et al., 
2000). Similarly, increased ET-1 staining in various cancer cell lines, in human patients 
with prostate cancer and pituitary adenoma, and in ischemic rat colon tissues, compared 
with control tissues, has been reported (Sugimachi et al., 2000; Asham et al., 2001; de 
Matteis et al., 2001). Investigating the role of ET-1 in intestinal disorders using ET 
antagonists could further extend the clinical implications of this study.  
In conclusion, this study demonstrated the presence and distribution of ET-1 in 
the intestinal tract of normal horses suggesting its role in physiologic functions. The 
increased expression of ET-1 observed in affected intestinal segments supports the 
hypothesis that ET-1 is involved in the pathogenesis of ischemic injury in horses.  
4.5 Product Information 
aBeuthanasia-D®, Schering-Plough Animal Health, New Jersey. 
bNormal Goat serum, Vector Laboratories, Burlingame, Calif. 
cRabbit-anti endothelin, Peninsula Laboratories, Belmont, Calif. 
dVectastain, Elite ABC Kit, Vector Laboratories, Burlingame, Calif. 
 99
eEndothelin-1, Sigma-Aldrich Co, St. Louis, Mo. 
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DETECTION OF ENDOTHELIN-1 GENE EXPRESSION IN THE 
GASTROINTESTINAL TRACT OF CLINICALLY HEALTHY HORSES USING 
POLYMERASE CHAIN REACTION 
 
 




Endothelins (ET), a family of highly conserved 21 amino acid peptides, possesses 
potent vasoconstrictor activity and numerous other functions in mammals (Rubanyi and 
Polokoff, 1994). They were originally isolated from cultured porcine endothelial cells 
(Yanagisawa et al., 1988) and later expressed in other cell types in the nervous, urinary, 
respiratory and gastrointestinal systems (Rubanyi and Polokoff, 1994; Inagaki et al., 
1991). Three different isoforms of ET, including ET-1, ET-2 and ET-3, each encoded by 
a separate gene, have been identified in humans and other species (Inagaki et al., 1991; 
Inoue et al., 1989; Shiba et al., 1992). Endothelin isoforms are processed as large pre-
proforms and post-translationally processed to active peptides. Endothelin synthesis is 
regulated by various stimuli (hypoxia, hormones, cytokines) at the transcriptional level 
(Shiba et al., 1992; Levin, 1995; Elton et al., 1992; Yoshizumi et al., 1990). Endothelins 
exert their pharmacological action by binding to two distinct high affinity receptors 
subtypes, ETA and ETB, which are seven-transmembrane G-protein-coupled receptors 
(Inagaki et al., 1991) distributed widely in a variety of cell types including vascular 
smooth muscle, endothelial cells and macrophages. 
Endothelins are widely expressed in various mammalian tissues and organs 
including the gastrointestinal tract, and localization of ET receptors in the intestinal tract 
of bovine, rats, and other laboratory animal species has been documented (Inagaki et al., 
1991). These isopeptides have a variety of biological roles, including involvement in 
vasoconstriction, cell growth, and intestinal and bronchial smooth muscle contraction 
(Levin, 1995; Elton et al., 1992; Yoshizumi et al., 1990). Several inflammatory mediators 
such as vasopressin, angiotensin, lipopolysaccharide, tumor necrosis factor-α and 
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interleukins stimulate the synthesis of ET. Endothelin synthesis is also enhanced by a 
variety of other stimuli such as low shear stress and hypoxia (Levin, 1995; Elton et al., 
1992). Several studies have emphasized the gastrointestinal tract as a major target of the 
endothelins (Chou et al., 1995). High concentrations of plasma ET-1 have been observed 
in various pathological conditions such as sepsis, ulcerative colitis, Crohn’s disease and 
endotoxemia (Murch et al., 1992; Myhre et al., 1993). Recently, we observed increased 
circulating plasma ET-like immunoreactivity in horses with naturally acquired 
gastrointestinal tract disorders such as strangulation obstruction, enterocolitis and 
peritonitis (Ramaswamy et al., 2002). To our knowledge, no studies have reported ET-1 
gene expression in the gastrointestinal tract of horses. The expression and relative 
amounts of ET-1 gene expression in gastrointestinal segments should enable us to further 
determine the physiological and pathological role of ET-1 in the gastrointestinal tract in 
horses.  
We hypothesized that the ET-1 would be found in variable quantities from various 
segments of the intestinal tract extending from the duodenum to the right dorsal colon of 
healthy horses. The primary objective of the study reported here was to determine the 
presence of the equine ET-1 gene expression in different sections of the gastrointestinal 
tract of clinically healthy horses, using reverse-transcriptase polymerase chain reaction.  
5.2 Materials and Methods 
This study was approved by the Institutional Animal Care and Use Committee of 
Louisiana State University. Tissue samples from 6 clinically healthy horses donated for 
reasons unrelated to gastrointestinal tract disorders were obtained immediately after 
euthanasia with intravenous sodium pentobarbitala (100 mg/kg, IV). Samples were 
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collected from various sections of the gastrointestinal tract extending from the stomach to 
the large colon. For uniformity in tissue collection, the following landmarks were used: 
stomach (halfway around the greater curvature), duodenum (1 foot from pylorus), 
jejunum (25 foot from ileocecal junction), ileum (1 foot from the ileocecal junction), 
right dorsal colon (1 foot orad to diaphragmatic flexure), pelvic flexure and right ventral 
colon (1 foot from cecocolic orifice). A section of heart (left ventricular wall) tissues 
were also collected. Full-thickness tissue samples were collected, immediately snap 
frozen in liquid nitrogen and stored at –80°C until analyzed.  
Total RNA was extracted using TRI REAGENT LS according to the 
manufacturer’s instructionsb. The RNA samples were heat inactivated at 65°C for 10min 
and chilled on ice 2 min. The RNA samples were reverse-transcribed by adding 25 µL of 
DEPC treated water, 1 µL of oligo(dT) primers and Ready-To-GOTM You-Prime First-
Strand Beadsc. 
 Oligonucleotide primer pairs specific for the equine ET-1 gened were designed 
and synthesized in our laboratorye. The ET-1 gene was then amplified from the cDNA by 
use of primers specific for equine ET-1, 5´-AAGCAGGAAAAGAACTCAGGTGAG-3´ 
(FP) and 5´-CAGCCTTTCTCCATAGTGTCTTGG-3´ (RP). The ET-1 amplification 
product was predicted to be 202 bp in length. The PCR reaction mixture consisted of 3 
µL of cDNA, 1 µL of forward and reverse primers (20 µM), 10 µL of PCR buffer, 10 µL 
of dNTP, 0.5 µL of Taq polymerase, and a sufficient amount of distilled water to have a 
final volume of 100 µL. The PCR reactions were performed in a thermal cycler 
programmed as follows: initial denaturation at 96°C for 3 min; cDNA was amplified in 
35 cycles (94°C for 30 sec, 60°C for 30 sec, and 72°C for 30 sec). Subsequently, final 
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extension was performed at 72°C for 10 min. A negative control (no template) was run to 
avoid any false positive reactions from exogenous contaminating DNA. The gels were 
visualized with an ultraviolet transilluminator and the gels were photographed with a 
Fluor-STM Multi-imager. 
5.3 Results 
 We confirmed the identity of the PCR products by sequencing after extensive 
purification, using an automated DNA sequencerf. The resultant sequences were 
confirmed by comparison to the known published partial sequence of equine ET-1d. 
Agarose gel electrophoresis of PCR products from the various sections of the 
gastrointestinal tract tissues, including the stomach, duodenum, jejunum, ileum, right 
ventral colon, pelvic flexure and right dorsal colon, demonstrated the expected product 
sizes, (Figure 5.1) and are identical to the published nucleotide partial sequence. No 
amplification signal was noticed in the negative control samples.  
5.4 Discussion 
To our knowledge, this is the first study to demonstrate the presence of 
constitutively expressed of equine ET-1 gene in various sections of the gastrointestinal 
tract of horses. Although this study showed the presence of the ET-1 gene expression in 
the gastrointestinal tract of clinically healthy horses, it does not reveal any information 
regarding the cellular localization or differential expression of ET-1 within the 
gastrointestinal tract tissues or alterations with disease conditions. Endothelins are 
multifunctional, vasoconstricting peptides exhibiting vasoactive, inotropic, and mitogenic 
properties, and have the ability to modulate other hormone systems as well as intestinal, 
renal and pulmonary function (Rubanyi and Polokoff, 1994; Inagaki et al., 1991; Inoue et 
 















Figure 5.1 - Agarose gel (1.5 %) electrophoresis pattern of RT-PCR amplification 
products of equine ET-1 in tissues collected from different sections of gastrointestinal 
tract tissues of clinically healthy horses. Lane 1- stomach, Lane 2- duodenum, Lane 3- 
jejunum, Lane 4- ileum, Lane 5- right ventral colon, Lane 6- Marker (100bp), Lane 7-
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al., 1989; Shiba et al., 1992). Induction of ET-1 synthesis is controlled at the level of 
transcription of its precursor, preproendothelin-1. Therefore, the presence of ET-1 gene 
should directly reflect the relative amount of ET-1 peptide based on the assumption that 
there is no posttranscriptional regulation of ET-1. Endothelin isoforms are initially 
synthesized as large precursor polypeptides, pre-proET, that are cleaved at two pairs of 
basic amino acids to generate intermediate peptides, big ET-1. The big ET-1 is post-
translationally processed to active peptide, ET-1, by endothelin converting enzyme (ECE) 
present in the cell surface (Rubanyi and Polokoff, 1994). A number of studies on the 
distribution of the ET-1 mRNA in a variety of tissues such as stomach have been reported 
(Egidy et al., 2000; Guan, Chen and Qian, 1998). Expression of ET-1 mRNA has been 
reported in wide variety of cell types such as macrophages, vascular smooth muscle cells, 
myocytes, astrocytes and mast cells (Liu, Yamada, Ochi, 1998; Dikranian et al., 1994). 
The ET-1 and ET-3 peptides were shown to be present in the gastrointestinal tract of 
other species; they have been identified in rat gut mucosa by radioimmunoassay and by in 
situ hybridization (Takahashi et al., 1990, MacCumber et al., 1989). 
 Studies have shown the presence of ET-1 mRNA expression in a variety of tissues 
such as lung, uterus, ovary, stomach and intestinal tissues of rats (Takahashi et al., 1990). 
In rat large intestine, ET-1 has been identified in the lamina propria as single particles 
suggesting that this peptide has a role in villus motility (Dikranian et al., 1994). Studies 
have found ET-like immunoreactivity, binding sites for ET-1 and the presence of ECE 
mRNA in the human colon, and ET-1 seems to be a potent intestinal secretagogue that 
increases colon contraction by direct stimulation of smooth muscle (Mac Cumber et al., 
1989). However, sites of ET-1 synthesis in the equine intestinal tract and its relation to 
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physiological function (motility, secretion) and in pathological conditions such as 
ischemia-reperfusion injury, inflammatory bowel disease or post-operative ileus have yet 
to be determined.  
 The finding of ET-1 gene expression in different sections of the equine 
gastrointestinal tract is of particular importance owing to the multifunctional role of ET-1 
in the gastrointestinal tract of other species (Chou et al., 1995; Murch et al., 1992). 
Additionally, involvement of ET-1 in a variety of gastrointestinal tract disorders such as 
ischemia-reperfusion injury, inflammatory bowel disease, peritonitis, and paralytic ileus 
has been suggested in various species (Egidy et al., 2000). In horses, studies have 
implicated the role of ET-1 in the pathophysiology of chronic obstructive airway diseases 
and laminitis (Benamou et al., 1998; Katwa et al., 1999). In our recent study, we found 
increased plasma ET-like immunoreactivity in naturally acquired gastrointestinal 
disorders, compared with clinically healthy horses; specifically horses with strangulation 
obstruction, enterocolitis and peritonitis had the greatest concentrations, suggesting its 
potential role in these disorders (Ramaswamy et al., 2002).  
 Identification of ET-mRNA in the gastrointestinal tract of healthy horses suggests 
that intestinal segments may be a source of ET-1 production during gastrointestinal tract 
disorders as observed in our previous study (Ramaswamy et al., 2002). The RT-PCR 
conditions, including the optimization of primers used in this study, may be useful in 
analyzing the relative levels of ET-1 gene expression in pathophysiological conditions of 
horses using further quantitative or semi-quantitative PCR methods such as the 
ribonuclease protection and TaqMan assays. Taken together with the fact that ET-1 has 
specific receptors and pharmacological activities in these ET-1 producing tissues, our 
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study suggests that ET-1 may play an important role as a locally (and perhaps 
systemically) acting regulating/modifying physiological modulator and might be an 
important pathological mediator.   
 In conclusion, the present study identified the presence of the ET-1 gene expression 
in various sections of the gastrointestinal tract in healthy horses, suggesting a role of ET-
1 as a regulator of intestinal function. Studies showing the presence of ET-1 and the 
correlation with other findings with various disease conditions make it important to 
perform further studies such as in situ hybridization and quantitative studies (TaqMan 
assay) to determine the distribution and differential expression of ET-1 throughout the 
different segments of the gastrointestinal tract and within different components of the 
intestinal wall of clinically healthy horses.  
5.5 Product Information 
a Beuthanasia-D®, Schering-Plough Animal Health, NJ. 
b TRI REAGENT-LS®, Molecular Research Center Inc, Cincinnati, OH.  
cReady-To-GOTM You-Prime First-Strand Beads, Amersham Pharmacia Biotech Inc, 
Piscataway NJ.  
dGenBank Accession AF130760, National Center for Biotechnology Information 
(NCBI) National Library of Medicine (NLM) at National Institute of Health  (NIH), 
Bethesda, Md. 
e Gene Lab, College of Veterinary Medicine, Louisiana State University, Baton Rouge  
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Endothelin-1 (ET-1), a 21 amino acid vasoconstrictor peptide, is expressed in a 
variety of cell types including endothelial cells, mast cells, macrophages, mesangial cells, 
and central and peripheral neurons (Takahashi et al., 1990; Rubanyi and Polokoff, 1994). 
Endothelins have been suggested to play a broader role in diverse physiological functions 
such as intestinal secretions, motility, maintenance of vasomotor tone, and closure of the 
patent ductus arteriosus (Shahbazian and Holzer, 2000; Rubanyi and Polokoff, 1994; 
Coceani, Kelsey, Seidlitz, 1992). Endothelin-1 exerts its biologic activity by binding to 
its receptors, ETA and ETB. The ETA receptors are located on smooth muscle and mediate 
contraction. On the other hand, the vascular ETB receptors, ETB2 are located on 
endothelial cells and mediate relaxation by the release of nitric oxide (NO). The ETB 
receptors, ETB1 on non-vascular smooth muscle mediate constriction (Clozel et al., 1992). 
Actions of ET-1 in intestinal smooth muscle are complex, and involve both excitatory 
and inhibitory effects depending on the type of receptor, section of tissue and species 
involved (Takahashi et al., 1990; Bolger et al., 1990; Eglen et al., 1989). Most of the 
actions of endothelins in the gastrointestinal tract are contractile and occur via their direct 
actions on the smooth muscle (Okabe et al., 1995). 
Gastrointestinal motility is regulated by the enteric nervous system together with 
excitatory and inhibitory neurons of the nonadrenergic- noncholinergic (NANC) system 
(Van Hoogmoed et al., 2000; Malone et al., 1999). Endothelins are shown to be localized 
in the enteric nervous system (Takahashi et al., 1990; Inagaki et al., 1991) and have been 
proposed to exert important modulatory actions on gastrointestinal motility (Takahashi et 
al, 1990; Allcock et al., 1995; Miasiro et al., 1999). The involvement of ET-1 in intestinal 
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motor regulation is due to the presence of both types of ET receptors, ETA and ETB, in the 
gastrointestinal tract (Inagaki et al., 1991; Yoshinaga et al., 1992). Endothelin-1 caused 
concentration-dependent contraction in isolated longitudinal smooth muscle of rat cecum 
and in opossum internal anal sphincter smooth muscle (Okabe et al., 1995 Chakdar and 
Rattan, 2001).  
The role of NANC innervation in the gastrointestinal tract has been studied in a 
variety of species, including rats, sheep, cats and horses (Venkova and Krier, 1994; Reid 
and Titchen, 1988; Van Hoogmoed et al., 2000).  Functions of the NANC inhibitory 
components have been detected in jejunum and ventral colon of horses (Van Hoogmoed 
et al., 2000; Malone et al., 1999). The role of nitric oxide (NO) and vasoactive intestinal 
peptide (VIP) in inhibitory neurotransmission in the equine jejunum and ventral colon has 
been reported using pharmacological agents (Van Hoogmoed et al., 2000; Rakestraw et 
al., 1996). The NO released from NANC allows receptive relaxation aboral to bolus 
during peristalsis. In horses, motility disorders are associated with a variety of pathologic 
conditions, including impaction, postoperative ileus, endotoxemia, and peritonitis 
(Blikslager et al., 1994; Alican et al., 1998). Luminal distention associated with 
impaction, strangulation obstruction, and ischemic injury results in gastrointestinal 
motility disturbances by interfering with the functions of various neurotransmitters such 
as NO, acetylcholine (ACh), norepinephrine (NE) and VIP. No studies have been 
reported regarding the role of ET-1 in the gastrointestinal tract of healthy horses. A study 
on isolated cecal tissue will allow a more definitive evaluation of the presence of ET 
receptors on cecal smooth muscle and its potential role in cecal motility. 
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We hypothesized that ET-1 would cause concentration dependent contraction of 
cecal longitudinal smooth muscle, mediated by ETA and ETB receptors. Also, we 
hypothesized that ET-1 will cause contractions similar to those produced by carbachol in 
equine longitudinal smooth muscle. The purposes of the study reported here was to 
characterize the ET-1 mediated responses in isolated equine cecal longitudinal smooth 
muscle and compare them with carbachol, a well-known intestinal smooth muscle 
contractile agent. Additionally, the role of ETA and ETB receptors in the mediation of ET-
1 induced responses in equine cecal longitudinal smooth muscle was studied using 
specific ET receptor antagonists. 
6.2 Materials and Methods 
6.2.1 Animals and Tissue Collection  
The study was approved by the Louisiana State University Institutional Animal 
Care and Use Committee. Tissues collected from adult healthy horses (n=36) that were 
destined for euthanasia for reasons unrelated to any apparent gastrointestinal tract or 
systemic diseases were used.  Tissues were collected immediately after euthanasia with 
an overdose of pentobarbital sodiuma (100 mg/kg, IV). A 15-cm long segment from the 
cecal base along the ventral taenia was collected, ingesta were gently removed by lavage 
with 0.9% NaCl and the tissue was placed in a beaker containing oxygenated, modified 
Kreb’s solution. The tissue segments were pinned flat in a dissecting bath containing 
sufficient warm (37˚C) oxygenated Kreb’s buffer solution to ensure that tissues were 
completely immersed, and bubbled with a mixture of 95% O2 and 5% CO2. The intestinal 
mucosa and submucosa were removed gently with sharp dissecting scissors and strips 
measuring 2-mm wide and 10-mm long were cut parallel to the taenia to obtain 
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longitudinal muscle sections and perpendicular to the taenia to obtain circular smooth 
muscle strips. All samples were tested in duplicate. 
6.2.2 Drugs and Reagents 
All solutions were prepared on the day of the experiment. Endothelin-1b, ETA 
receptor antagonist (BQ-123)c and ETB receptor antagonist (IRL-1038)d, carbachole, 
atropinef, and guanethidineg and tetrodotoxinh were used. The drugs were dissolved 
according to manufacturer’s instructions with distilled water. The ET-1 was reconstituted 
in distilled water and stored in aliquots of 10-4M at –80˚C. Aliquots were thawed 
immediately prior to use and further diluted to the desired concentration. Carbachol was 
dissolved in distilled water immediately before use. The composition of modified Kreb’s 
solution was as follows [mM]: NaCl, 118; MgSO4, 1.2; CaCl2, 2.5; KCl, 4.7; NaHCO3, 
24.9; and dextrose [pH 7.3 to 7.4]. 
Preliminary studies (n=6) were conducted to determine the appropriate resting 
tension and equilibration period for tissues to determine the effect of ET-1. Results from 
our study showed that a resting tension of 2 g was required to elicit a consistent 
contractile pattern, which is similar to previously reported studies (Van Hoogmoed et al., 
2000; Rakestraw et al., 1996; Malone et al., 1999). Both longitudinal and circular muscle 
strips exhibited spontaneous contractile activity. The spontaneous activity of 
longitudinally-oriented smooth muscle was cyclic and occurred at a steady rate of 
approximately of 2-3 contractions per minute (25mm/min). The circular smooth muscle 
occurred in a pattern typical to that of colonic tissue, however, the pattern of contractions 
during the 3-minute period didn’t sufficient enough to evaluate the response of 
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exogenous agents added. So further experiments were conducted on longitudinal smooth 
muscle. 
6.2.3 Experimental Protocol 
One end of each strip was mounted to the floor of the organ bath (10 ml) and the 
other end was attached to a force-displacement transduceri, interfaced with a polygraphj, 
to record the change in tension. For evaluation of tissue responses, intestinal smooth 
muscle tissues were equilibrated for 45-minutes in the organ baths containing Kreb’s 
solution maintained at 37˚C by a circulating water and oxygenated with a gas mixture of 
95% O2 and 5% CO2. Resting tension was set at 2 grams and tissues were allowed to 
equilibrate for an additional 60 minutes. Throughout the experiment, Kreb’s solution was 
changed at 15-minute intervals. 
  Based on preliminary studies, further experiments were performed to 
characterize the role of ET-1 in the longitudinal smooth muscle. Tissues from 6 horses 
(48 strips) were used for determining the concentration-response (C-R) relationships of 
both ET-1 and carbachol and 18 horses (104 strips) were used for C-R relationships of 
ET-1 in the presence of ETA and ETB receptor antagonists, separately and together. 
6.2.3.1 Concentration-Response Relationships of Carbachol and ET-1 on Cecal 
Longitudinal Smooth Muscle 
 
After a 95-minute equilibration period, cumulative C-R relationships for ET-1 and 
carbachol at graded concentrations of 10-9, 10-8, 10-7 and 10-6 M were performed in 





6.2.3.2 Effect of ET Antagonists, BQ-123, IRL-1038, Separately and Together on 
ET-1 Induced Response 
 
After the application of 2 g tension, the tissues were incubated separately with 
ETA (BQ-123) and ETB (IRL-1038) antagonists, at 3 concentrations of 10-9, 107 and 10-5 
M, for a period of 45 minutes, and a C-R relationship of ET-1 (10-9 to 10-6M) was then 
determined. Similarly, cecal muscle strips were incubated with 3 individual 
concentrations of 10-9, 107 and 10-5M of the combined antagonists for a period of 45 
minutes, and a C-R relationship of ET-1 (10-9 to 10-6M) was determined as before.  
6.2.3.3 Electrical Field Stimulation (EFS) 
The electrodes used for the EFS consisted of a pair of platinum wires fixed at both 
sides of the smooth muscle strip. Electric field stimulation was generated by a stimulatork 
and applied to all tissues simultaneously. Repetitive stimuli (trains) at 3-minute intervals 
of millisecond duration pulses were tested at intensities of 40V and 60V, with frequency 
of 5Hz, 10 Hz and 20Hz to the cecal longitudinal smooth muscle preparations. These 
stimulation parameters have been shown to cause facilitate intestinal smooth muscle 
responses in horses (Malone et al., 1999).  In our study, tissues were given repetitive 
stimuli at 3-minute trains of 10 millisecond duration pulses at intensities of 60V and 
20Hz to the longitudinal smooth muscle preparation. Tissues from 5 horses were 
prepared as before and allowed to equilibrate for 1 hr, after which a resting tension of 2 g 
was set and EFS applied. In a separate set of experiments, after equilibration, tissues were 
incubated with atropine (10-5M) and guanethidine (10-5M) for 45 minutes and EFS was 
applied. Tetrodotoxin (10-3M), a sodium channel blocker, was added to test the role of 
nerve conduction in the EFS induced contractions.  
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6.3 Data analysis  
The percentage changes in baseline tension were quantified by measuring 
percentage change in the area under the curve (AUC) using Image Analysis Softwarel. 
The active change in tissue responses was calculated as the percentage change from 
baseline tension. The percentage change in baseline tension for ET-1 responses was 
calculated by measuring the AUC 3-minutes prior to the addition of the drug compared 
with the AUC during the 3-minute period after each dose was added (Rakestraw et al., 
1996). The changes in tension due to ET-1 were compared with carbachol and with and 
without the ET receptor antagonists. 
All data were considered continuous and followed a normal distribution as noted 
by failure to reject the null hypothesis of normality at P <0.05, using the Shapiro-Wilk 
test. The data were summarized as mean ± SEM and was evaluated for an effect of 
antagonist and concentration, using a mixed linear model accounting for the random 
variance of horse. Where there were significant interaction effects at P <0.05, 
predetermined multiple comparisons were made across concentrations within each 
antagonist group, and between groups at specified concentrations, using least squares 
means maintaining type I error at 0.05. PROC UNIVARIATE and PROC MIXED were 
used for the analysis using software.m 
6.4 Results 
Both longitudinal and circular smooth muscle showed spontaneous contractile 
activity (Figure 6.1). The addition of ET-1 produced a slow sustained, concentration-
dependent contractile response in equine cecal longitudinal muscle (Figure 6.2). The 
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Figure 6.1 Physiograph recording (25 mm/sec) of cecal circular (A) and longitudinal (B) 
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Figure 6.2 - Physiograph recording (25 mm/sec) of cecal longitudinal muscle contractile 
















(Figure 6.3).Pre-incubation of cecal longitudinal muscle strips with the ETA receptor 
antagonist, BQ-123, did not inhibit the contractile response of ET-1 (Figure 6.4). A slight 
non-significant increase in contractile activity was observed in tissues pre-incubated with 
BQ-123 (10-9, 10-7 M), compared with that of control tissues (P>0.05). Similarly, pre-
incubation of tissues with the ETB receptor antagonist, IRL-1038, did not abolish ET-1 
induced response (Figures 6.4 & 6.5). The contractile responses of longitudinal tissue to 
ET-1 were significantly decreased when tissues were pre-incubated with BQ-123 and 
IRL-1038 together at 10-5M concentrations, compared with tissues incubated with lower 
dose of the both receptor antagonists (10-7, 10-9 M) and compared with control tissues 
receiving no antagonists (Figure 6.6). Contractile activity of the longitudinal muscle 
strips was not affected by EFS in both control tissues and those incubated with atropine 
and guanethidine. Also, the addition of tetrodotoxin did not alter the contractile activity 
of cecal longitudinal smooth muscle.  
6.5 Discussion  
This study demonstrated that ET-1 causes a concentration-dependent contraction 
of longitudinal smooth muscle of the equine cecum. The response of longitudinal smooth 
muscle to ET-1 was significantly less than with the muscarinic agonist, carbachol, on an 
equimolar concentration basis. It appears that the magnitude of ET-1 induced contractile 
response is of lesser magnitude in intestinal smooth muscle compared to that of ET-1 
effect in the large intestinal vasculature of horses (Venugopal et al., 2001). Pre-
incubation of longitudinal muscle strips with the ET antagonists, BQ-123 and IRL-1038, 
at any concentration did not cause a significant reduction in the response induced by ET-
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Figure 6.3- Mean ± SEM % change in area under the curve (AUC) in equine longitudinal 
smooth muscle to log molar concentrations of endothelin-1 and carbachol. *Significant 
differences (P<0.0001) in response for ET-1 and carbachol were observed at log molar 




























                
ETA Antagonist Study























Figure 6.4 - Mean ± SEM % change in area under the curve (AUC) in equine 
longitudinal smooth muscle to log molar concentrations of endothelin-1 before (control) 
and after incubation of tissues with different log molar concentrations (10-9 M, 10-7 M and 

























                
ETB Antagonist Study
























Figure 6.5 - Mean ± SEM % change in area under the curve (AUC) in equine 
longitudinal smooth muscle to log molar concentrations of endothelin-1 before (control) 
and after incubation with different log molar concentrations (10-9 M, 10-7 M and 10-5 M) 


























              
ETA + ETB Antagonist study























Figure 6.6 - Mean ± SEM percentage change AUC in equine longitudinal smooth muscle 
to log molar concentrations of endothelin-1 before (control) and after incubation with 
different log molar concentrations (10-9 M, 10-7 M and 10-5 M) of an endothelin receptor-
A and B antagonist (BQ-123 and IRL-1038) together. Contractile responses to ET-1 were 
*significantly decreased when tissues were incubated with both antagonists at 10-5 M log 




contractile effects of ET-1 were significantly inhibited. These findings suggest that both 
endothelin receptors, ETA and ETB, mediate contraction in response to ET-1 in the cecal 
longitudinal smooth muscle.   
Along with branches of both autonomic nervous systems, intestinal peristalsis is 
coordinated and controlled by the enteric nervous system (Van Hoogmoed et al., 2000). 
The shortening and constricting movements of the equine cecum occur by the 
synchronized contractions of circular and longitudinal smooth muscle, occurring 
approximately every 4 minutes (Sellers and Lowe, 1986). Any lack of coordination 
between activities of the smooth muscle layers can result in motility dysfunction. 
Endothelin-1 is the most potent vasoconstrictor known to date, and its effect on intestinal 
muscle varies depending on the type of tissue, section of the gastrointestinal tract and 
species tested (Borges et al., 1989; Bolger et al., 1992; Takahashi et al., 1990; Eglen et 
al., 1989). The ET-1 mediated contraction depends on the release of both intracellular 
calcium and the entry of extracellular calcium (Yoshinaga et al., 1992). Both ETA and 
ETB receptors are involved in the activation of gastrointestinal motility in guinea pig 
ileum (Miasiro et al., 1995). Elevated plasma endothelin-1 like immunoreactivity has 
been implicated with intestinal dysmotility in human patients with acute pancreatitis 
(Chen et al., 1999). However, no studies have reported the role of ET-1 in intestinal 
motility or dysmotility of horses.  
Endothelins are found in enteric neurons with binding sites in the myenteric and 
submucosal plexus, mucosa, muscular layers and in the vasculature of rat colon 
(Takahashi et al., 1990). Endothelin receptors have the greatest distribution in cecum and 
stomach, compared with other sections of the guinea pig intestine (Kuwahara et al., 
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2000). In the gastrointestinal tract, the contractile effect of ET-1 has been reported in the 
guinea pig ileum (Bolger et al., 1992; Ishida et al., 1989) and the stomach and colon of 
rats (Takahashi et al., 1990). Endothelin-1 causes a marked biphasic response in guinea 
pig ileal longitudinal smooth muscle with a similar magnitude to that observed in 
vascular smooth muscle (Lin and Lee, 1990; Miasiro et al., 1999). Okabe et al. (1995) 
reported direct contractile effect of ET-1 in both longitudinal and circular smooth muscle 
cells. In our study, ET-1 caused a slow, sustained concentration-dependent contractile 
response (10-9 M to 10-6 M). The concentrations tested for ET-1, may or may not of 
physiological concentration range, however, various neurotransmitters are found in 
macromolar concentration. Also the degree of contraction of longitudinal smooth muscle 
to ET-1 was significantly lower compared with that of muscarinic agonist, carbachol. The 
contractile response of ET-1 in longitudinal smooth muscle was lower than the reported 
effect of ET-1 in the colonic vasculature of horses (Venugopal et al., 2001). This 
difference in the magnitude of the contractile response of ET-1 between vascular and 
non-vascular smooth muscle has been documented in other species (Fulginiti et al., 
1993), suggesting that ET-1 has more potent contractile effects in vascular smooth 
muscle than in intestinal smooth muscle.   
Endothelin-1 has been implicated in regulation of gastrointestinal motility and in 
the pathogenesis of ischemia and ischemia-reperfusion (I-R) injury (Tekin et al., 1999; 
Anadol et al., 1998). Treatment with bosentan (ETB receptor antagonist) abolished I-R 
injury induced intestinal transit delay suggesting that I-R associated delays in intestinal 
transit involve an endothelin-dependent mechanism (Alican et al., 1998). Also, a 
beneficial effect of ETA antagonists in reducing ET-1 induced gastric and intestinal 
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mucosal damage in rats has been reported (Massberg et al., 1998). The ET antagonists 
BQ-123 and IRL-1038 used in our study are specific competitive endothelin receptor 
antagonists that block ETA and ETB receptors, respectively. In our study, the epithelial 
mucosal and submucosal layer of the cecal tissues was removed for evaluating ET-1 
response in the longitudinal smooth muscle. The ET receptors present in the muscular 
layer of gastrointestinal smooth muscle are ETA and ETB2 receptor types, and both 
mediate contractile response on binding to ET-1. 
Pre-incubation of tissues with ETA receptor antagonist, BQ-123 (10-9 M, 10-7M, 
10-5 M) did not significantly alter the ET-1 induced contractile response. However, the 
contractile responses were slightly reduced on tissues pre-incubated with ETA receptor 
antagonist at 10-5 M though it was not significantly different from other treatments 
(Figure 6.4). Also the contractile response of ET-1 was slightly greater in tissues treated 
with 10-7 and 10-9 M compared to control. No significant difference in contractile 
response to ET-1 was seen in tissues pre-incubated with ETB receptor antagonist, IRL-
1038 at any concentration (Figure 6.5). Thus, pre-incubation of tissues separately with 
BQ-123 and IRL-1038 did not significantly alter the ET-1 induced changes in cecal 
longitudinal muscle tension. The contractile response to ET-1 was completely abolished 
when tissues were incubated with both antagonists combined at 10-5 M concentration. 
This type of response may be explained by the fact that when one receptor type is 
blocked (ETA) the other receptor (ETB2) effects are unmasked to induce a contractile 
effect, and vice versa. This could also suggest that both ETA and ETB receptors mediate 
contraction of cecal longitudinal smooth muscle when ET-1 binds. Similarly, studies 
using an ETA receptor antagonist (BQ 123) and a combined ETA / ETB receptor 
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antagonist (PD145065) showed that both endothelin ETA and ETB2 receptor types 
mediate contraction in the guinea pig ileum (Miasiro et al., 1995).  
Under our experimental conditions, the contractile activity of the cecal 
longitudinal smooth muscle layer was unaffected with EFS. Similarly, unlike in circular 
smooth muscle, the contractile activity of the ventral colon longitudinal muscle strips of 
horses was unaffected by EFS (Van Hoogmoed et al., 2000). The lack of EFS response in 
our study can be speculated to be due either an insufficient release of neurotransmitter to 
elicit a response or the effects of neurotransmitters were not sufficient to override the 
intrinsic contractile (spontaneous contraction) responses. 
In summary, ET-1 caused a concentration-dependent contractile effect on cecal 
longitudinal smooth muscle of clinically healthy horses, which appears to be mediated by 
both ETA and ETB receptors. However, the ET-1 induced contraction in cecal 
longitudinal smooth muscle was not as pronounced as observed in equine vascular 
smooth muscle and was less than carbachol-treated cecal smooth muscle. The observed 
effects of ET-1 on cecal longitudinal smooth muscle contraction may suggest that 
alterations in cecal motility might be associated with changes in ET-1 synthesis and 
release during naturally acquired gastrointestinal tract disorders. Further studies are 
needed to determine the role of ET-1 in the smooth muscle responses of diseased or 
affected tissues. 
6.6 Product Information  
aBeuthanasia-D, Schering-Plough Animal Health Corp, Union, NJ. 
bEndothelin-1, American Peptide Company, Sunnyvale, Calif. 
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 cBQ-123, American Peptide Company, Sunnyvale, Calif. 
dIRL-1038, American Peptide Company, Sunnyvale, Calif. 
eCarbachol, Sigma-Aldrich Inc, St Louis, Mo.  
fAtropine, Sigma-Aldrich Inc, St Louis, Mo. 
gGuanathedine, Sigma-Aldrich Inc, St Louis, Mo. 
hTetrodotoxin, Sigma-Aldrich Inc, St Louis, Mo. 
iModel 7D polygraph, Grass instruments, Quincy, Mass. 
jChart recorder model 25-60, Grass instruments, Quincy, Mass. 
kGrass S48 stimulator, Astro-Med Inc, Grass Instruments Division, West Warwick, RI.  
kSigma Scan Pro 4.0, Jandel Scientific Software, San Rafael, Calif. 
lSAS for windows 95, version  7.0, SAS Systems Inc, Cary, NC.  
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Endothelin-1, the most potent vasoconstrictor known to date, has been implicated 
in a variety of physiological processes ranging from maintenance of vasomotor tone, ion 
secretion, closure of the patent ductus arteriosus and control of gastrointestinal tract 
motility. Also, ET-1 has been found to play a major role in the pathophysiology of 
intestinal ischemia, cerebral vasospasm, peritonitis, megacolon and cardiogenic shock. 
The maintenance of vascular tone and smooth muscle homeostasis is achieved mainly by 
ET-1 in conjunction with NO. An imbalance in the release of ET-1 and NO are believed 
to cause alterations in vasomotor tone and gastrointestinal motility. We investigated the 
role of ET-1 in the gastrointestinal tract of horses by measuring circulating concentrations 
of plasma ET-like immunoreactivity and characterized the role of ET-1 mediated 
responses in equine cecal longitudinal smooth muscle. Endothelin-1 gene expression was 
determined in different sections of the gastrointestinal tract of clinically healthy horses. 
We examined the regional distribution of ET-1 like immunoreactivity using 
immunohistochemical staining in the gastrointestinal tract of clinically healthy horses and 
compared this to intestinal segments collected from horses with acquired strangulation 
obstruction.    
 In the first study, we found increased concentrations of plasma ET-like 
immunoreactivity in horses with acquired gastrointestinal disorders, compared with 
clinically healthy horses. Median plasma concentrations of ET-like immunoreactivity 
were 1.80 pg/ml (range, 1.09 to 3.2 pg/ml) in healthy horses. Plasma ET-like 
immunoreactivity was greatest in horses with strangulating large intestinal obstruction 
(median, 10.02pg/ml; range, 3.8 to 22.62 pg/ml), peritonitis (9.19pg/ml; 7.89 to 25.83 
pg/ml), and enterocolitis (8.89 pg/ml, 6.30 to 18.36 pg/ml). Also, the concentration of 
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ET-like immunoreactivity was significantly associated with survival, PCV, and duration 
of signs of pain. The source of measured ET-like immunoreactivity in plasma remains 
unclear. The increased circulating concentrations levels of ET-1 may be from the 
damaged endothelium, from affected tissues or may be a result of hemoconcentration in 
affected horses. Greater than 80% of the ET-1 synthesized by the endothelium is secreted 
abluminally toward the tunica media where it functions in a paracrine fashion. Therefore, 
measurement of plasma ET-1 concentrations may not truly reflect the overall synthesis 
and release of ET-1 during pathophysiologic events. However, the significant increase in 
ET-1 like immunoreactivity in severe intestinal disorders such as strangulating 
obstruction and peritonitis, compared with other less severe disorders, indicates a 
potential involvement of ET-1 in these disorders.  
Immunohistochemical studies revealed regional distribution of ET-1 like 
immunoreactivity in different segments of the equine gastrointestinal tract extending 
from the duodenum to the right dorsal colon. The ET-1 like staining is confined to the 
cytoplasm of the surface epithelium, villi, the muscular layer, and less intense staining in 
the epithelial crypts. The endothelial lining of the blood vessels stained with veins stained 
more intensely than arteries. The presence of ET-1 in the surface epithelial cells suggests 
the potential physiological role of ET-1 in ion secretion and intestinal motility. This 
function of ET-1 has previously been shown in rat and human colon. This is the first 
study to report the presence of ET-1 in the gastrointestinal tract of horses. An increase in 
the intensity of ET-1 staining from intestinal segments from horses with acquired small 
intestinal and large colon strangulation obstruction, compared with intestinal segments 
from healthy horses, was observed.   
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We identified ET-1 gene expression in various sections of the gastrointestinal 
tract of the clinically healthy horse, suggesting a role of ET-1 in the regulation of 
intestinal function. Therefore, the intestinal segments may be a source of ET-1 synthesis 
and release during gastrointestinal tract disorders as observed in our previous study. 
Studies showing the presence of ET-1 and the correlation with other findings in various 
disease conditions justifies the need to perform further studies such as in situ 
hybridization and quantitative studies to determine the differential expression of ET-1 in 
acquired gastrointestinal tract disorders of horses. 
We characterized the role ET-1 mediated responses in equine cecal longitudinal 
smooth muscle in vitro. Despite the dose-dependent increase in contractile activity of ET-
1 in spontaneously contracting equine longitudinal smooth muscle, the magnitude was 
much less compared with the muscarinic agonist, carbachol. The effects of ET-1 on 
intestinal smooth muscle occur by binding of ET-1 to its specific ET receptors types, ETA 
and ETB. Binding of ET-1 to ETA in smooth muscle, and ETB in vascular endothelium 
mediate contraction and dilatation, respectively. However, these responses vary 
depending upon the tissues and species tested.  Incubation of cecal longitudinal muscle 
separately with BQ-123 (ETA blocker) or IRL-1038 (ETB blocker) did not significantly 
inhibit the contractile activity to ET-1 at any concentration (10-9M, 10-7M, 10-5M). 
However, contractile responses of cecal longitudinal smooth muscle to ET-1 were 
significantly inhibited when tissues were incubated simultaneously with both antagonists 
at a concentration of 10-5M (P<0.001). This suggests that both receptors ETA and ETB 
receptors are likely involved in the contractile effect. The results from this study suggest 
the presence of ETA and ETB receptors in the gastrointestinal tract and that they likely 
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mediate the contractile effect of ET-1 in cecal smooth muscle of horses. However, 
findings from these studies do not explain the importance of ET-1 in intestinal motility 
disorders, which will require further evaluation in affected intestinal segments.  
In summary, the circulating concentrations of plasma ET-l may be a potential 
indicator of severity of the gastrointestinal tract disorders in horses. Endothelin-1 gene 
expression was detected in different sections of intestine including the duodenum, 
jejunum, ileum, pelvic flexure and colon; as well as in the heart and lung. 
Immunohistochemical localization of ET-1 like immunoreactivity in the surface 
epithelium, villi and blood vessels in various segments of intestinal tract of healthy horses 
and those with intestinal strangulation obstruction indicates its potential role in intestinal 
secretions and motility. In horses, both ETA and ETB receptors mediate the ET-1 induced 
contractile response in cecal longitudinal smooth muscle. Further investigation is 
warranted to further characterize the role of ET-1 in the gastrointestinal tract of horses 
during health and disease. Additionally, the benefit of ET antagonists in attenuating 
motility disturbances and other disorders involving the intestinal vascular and 
nonvascular smooth muscle of horses to be evaluated.  
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